<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Dydrogesterone</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Dydrogesterone">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Dydrogesterone</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Dydrogesterone</b>, sold under the brand name <b>Duphaston</b> and <b>Femoston</b> (as Menopausal Hormone Therapy), is a progestin medication which is used for a variety of indications, including threatened or recurrent miscarriage during pregnancy, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhea, irregular cycles, premenstrual syndrome, and as a component of menopausal hormone therapy.<span class="mw-ref" id="cite_ref-pmid16112947_6-1"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-pmid16112947_6-2"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>



<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Dydrogesterone</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Dydrogesterone.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Dydrogesterone.svg.png" data-file-width="512" data-file-height="377" data-file-type="drawing" height="166" width="225"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Dydrogesterone_molecule_ball.png" tppabs="https://ptable.com/wiki/compounds/I/m/Dydrogesterone_molecule_ball.png" data-file-width="2320" data-file-height="1943" data-file-type="bitmap" height="197" width="235"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Dydroboon, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>Isopregnenone; Dehydroprogesterone; Didrogesteron; 6-Dehydroretroprogesterone; 9β,10α-Pregna-4,6-diene-3,20-dione; NSC-92336<span class="mw-ref" id="cite_ref-Elks2014_1-0"><a href="#cite_note-Elks2014-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-0"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/international/dydrogesterone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/dydrogesterone.html'" tppabs="https://www.drugs.com/international/dydrogesterone.html" class="external text external">International Drug Names</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Progestogen; Progestin</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>G03DB01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=G03DB01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=G03DB01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=G03DB01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>28%<span class="mw-ref" id="cite_ref-Femoston-Label_3-0"><a href="#cite_note-Femoston-Label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Schindler2015_4-0"><a href="#cite_note-Schindler2015-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>? (probably to <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a>)<span class="mw-ref" id="cite_ref-FRCOG2015_5-0"><a href="#cite_note-FRCOG2015-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_6-0"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Hepatic: AKR1C1, AKR1C3, CYP3A4<span class="mw-ref" id="cite_ref-OlbrichWeigl2016_7-0"><a href="#cite_note-OlbrichWeigl2016-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-BeraničGobec2011_8-0"><a href="#cite_note-BeraničGobec2011-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolites</th><td><abbr>20α-DHD</abbr> (exclusively via AKR1C1 and AKRC13)<span class="mw-ref" id="cite_ref-BeraničGobec2011_8-1"><a href="#cite_note-BeraničGobec2011-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td><abbr>Parent</abbr>: 5–7 hours<span class="mw-ref" id="cite_ref-BińkowskaWoroń2015_9-0"><a href="#cite_note-BińkowskaWoroń2015-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><br><abbr>Metabolite</abbr>: 14–17 hours<span class="mw-ref" id="cite_ref-BińkowskaWoroń2015_9-1"><a href="#cite_note-BińkowskaWoroń2015-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Urine</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(8<i>S</i>,9<i>R</i>,10<i>S</i>,13<i>S</i>,14<i>S</i>,17<i>S</i>)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[<i>a</i>]phenanthren-3-one</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152-62-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152-62-5'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152-62-5" class="external text external">152-62-5</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/9051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/9051'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/9051" class="external text external">9051</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00378  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00378'" tppabs="https://www.drugbank.ca/drugs/DB00378" class="external text external">DB00378</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.8699.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.8699.html'" tppabs="http://www.chemspider.com/Chemical-Structure.8699.html" class="external text external">8699</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=90I02KLE8K  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=90I02KLE8K'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=90I02KLE8K" class="external text external">90I02KLE8K</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D01217  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D01217'" tppabs="https://www.kegg.jp/entry/D01217" class="external text external">D01217</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31527'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31527" class="external text external">CHEBI:31527</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID1022974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID1022974'" tppabs="https://comptox.epa.gov/dashboard/DTXSID1022974" class="external text external">DTXSID1022974</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.005.280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.005.280'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.005.280" class="external text external">100.005.280</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>21</sub><span>H</span><sub>28</sub><span>O</span><sub>2</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td>312.446<span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC4%5CC%3DC3%5CC%3DC%2F%5BC%40%40H%5D1%5BC%40%40H%5D%28CC%5BC%40%40%5D2%28%5BC%40%40H%5D%28C%28%3DO%29C%29CC%5BC%40%40H%5D12%29C%29%5BC%40%5D3%28C%29CC4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC4%5CC%3DC3%5CC%3DC%2F%5BC%40%40H%5D1%5BC%40%40H%5D%28CC%5BC%40%40%5D2%28%5BC%40%40H%5D%28C%28%3DO%29C%29CC%5BC%40%40H%5D12%29C%29%5BC%40%5D3%28C%29CC4'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC4%5CC%3DC3%5CC%3DC%2F%5BC%40%40H%5D1%5BC%40%40H%5D%28CC%5BC%40%40%5D2%28%5BC%40%40H%5D%28C%28%3DO%29C%29CC%5BC%40%40H%5D12%29C%29%5BC%40%5D3%28C%29CC4" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>144<span>&nbsp;</span>°C (291<span>&nbsp;</span>°F)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Boiling point</th><td>463<span>&nbsp;</span>°C (865<span>&nbsp;</span>°F)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Solubility in water</th><td>Insoluble<span>&nbsp;</span>mg/mL (20<span>&nbsp;</span>°C)</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C4\C=C3\C=C/[C@@H]1[C@@H](CC[C@@]2([C@@H](C(=O)C)CC[C@@H]12)C)[C@]3(C)CC4</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:JGMOKGBVKVMRFX-HQZYFCCVSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=461091780&page2=Dydrogesterone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=461091780&page2=Dydrogesterone'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=461091780&page2=Dydrogesterone" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Side effects of dydrogesterone include menstrual irregularities, headache, nausea, breast tenderness, and others.<span class="mw-ref" id="cite_ref-MishellKirschbaum1990_10-0"><a href="#cite_note-MishellKirschbaum1990-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Femoston-NHS_11-0"><a href="#cite_note-Femoston-NHS-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Dydrogesterone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like <a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">progesterone</a>.<span class="mw-ref" id="cite_ref-pmid16112947_6-3"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid19969432_12-0"><a href="#cite_note-pmid19969432-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> The medication is an atypical progestogen and does not inhibit ovulation.<span class="mw-ref" id="cite_ref-pmid16112947_6-4"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Tausk1972_13-0"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> It has weak antimineralocorticoid activity and no other important hormonal activity.<span class="mw-ref" id="cite_ref-pmid16112947_6-5"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid19969432_12-1"><a href="#cite_note-pmid19969432-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


<p>Dydrogesterone was developed in the 1950s and introduced for medical use in 1961.<span class="mw-ref" id="cite_ref-Publishing2013_14-0"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> It is available widely throughout Europe, including in the United Kingdom, and is also marketed in Australia and elsewhere in the world.<span class="mw-ref" id="cite_ref-IndexNominum2000_2-1"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Publishing2013_14-1"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> The medication was previously available in the United States,<span class="mw-ref" id="cite_ref-Publishing2013_14-2"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> but it has been discontinued in this country.<span class="mw-ref" id="cite_ref-Manu2000_15-0"><a href="#cite_note-Manu2000-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Dydrogesterone has proven effective in a variety of conditions associated with progesterone deficiency,<span class="mw-ref" id="cite_ref-pmid14667985_16-0"><a href="#cite_note-pmid14667985-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Infertility due to luteal insufficiency<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> including threatened miscarriage,<span class="mw-ref" id="cite_ref-pmid20005647_19-0"><a href="#cite_note-pmid20005647-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> habitual or recurrent miscarriage,<span class="mw-ref" id="cite_ref-:0_20-0"><a href="#cite_note-:0-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Menstrual disorders<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> premenstrual syndrome,<span class="mw-ref" id="cite_ref-ReferenceA_22-0"><a href="#cite_note-ReferenceA-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> and endometriosis.<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Dydrogesterone has also been registered as a component of menopausal hormone therapy<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> to counteract the effects of unopposed <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogen</a> on the endometrium in women with an intact uterus.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Gynecological_disorders">Gynecological disorders</h3></summary>
    
<p>Primary or essential dysmenorrhea is a very common gynecological phenomenon experienced by women during their reproductive years. Clinical studies have shown symptom relief and a reduction in pain with dydrogesterone treatment for dysmenorrhea.<span class="mw-ref" id="cite_ref-pmid17943543_25-0"><a href="#cite_note-pmid17943543-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> Secondary amenorrhea is not a specific disease, but is instead a symptom. Dydrogesterone has been found to adequately induce bleeding within a sufficiently estrogen-primed endometrium. When <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a> levels are found to be low, dydrogesterone treatment is more effective when supplemented with estrogens.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>

<p>Endometriosis is a chronic disease which can cause severe, progressive, and at times, incapacitating dysmenorrhea, pelvic pain, dyspareunia and infertility. Dydrogesterone relieves pain without inhibiting ovulation, so that patients are able to become pregnant during treatment. Dydrogesterone is particularly suitable in cases where the woman desires to become pregnant and to prevent bleeding problems.<span class="mw-ref" id="cite_ref-pmid19945806_27-0"><a href="#cite_note-pmid19945806-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Dydrogesterone results in statistically significant reductions in the symptoms pelvic pain, dysmenorrhea and dyspareunia after the first treatment cycle for the treatment of post-laparoscopic endometriosis.<span class="mw-ref" id="cite_ref-pmid17943543_25-1"><a href="#cite_note-pmid17943543-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> The amount and duration of menstrual bleeding is also significantly reduced, and from the end of the third month onwards, bleeding was considered normal in the majority of patients. Improvement of endometriosis was observed in 71% of patients and cure in 21%.</p>

<p>Dydrogesterone has shown reasonable efficacy in relieving a number of premenstrual syndrome symptoms like mood swings and physical symptoms.<span class="mw-ref" id="cite_ref-ReferenceA_22-1"><a href="#cite_note-ReferenceA-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Cyclic treatment with low-dose (10<span>&nbsp;</span>mg/day) dydrogesterone has been found to be effective in the treatment of fibrocystic breast changes and associated breast pain.<span class="mw-ref" id="cite_ref-pmid12227885_28-0"><a href="#cite_note-pmid12227885-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Infertility_and_miscarriage">Infertility and miscarriage</h3></summary>
    
<p>Oral dydrogesterone is an effective medication, well tolerated and accepted among patients, and can be considered for routine luteal support. Advantage of dydrogesterone is oral administration, easy to use and better patient compliance which results in high satisfaction score of oral dydrogesterone in luteal support of IVF/ICSI cycles.<span class="mw-ref" id="cite_ref-pmid25622239_29-0"><a href="#cite_note-pmid25622239-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> Oral administration of progestins dydrogesterone at least similar live birth rate than vaginal progesterone capsules when used for luteal support in embryo transfer, with no evidence of increased risk of miscarriage.<span class="mw-ref" id="cite_ref-BarbosaValadares2018_30-0"><a href="#cite_note-BarbosaValadares2018-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-GriesingerBlockeel2018_31-0"><a href="#cite_note-GriesingerBlockeel2018-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>

<p>Threatened miscarriage is defined as bleeding during the first 20 weeks of pregnancy while the cervix is closed. It is the most common complication in pregnancy, occurring in 20% of all pregnancies. Recurrent abortion is defined as the loss of three or more consecutive pregnancies. Dydrogesterone is associated with approximately two-fold significant reduction in the miscarriage rate as compared to standard care in threatened and recurrent miscarriages with minimal side effects.<span class="mw-ref" id="cite_ref-:0_20-1"><a href="#cite_note-:0-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-pmid22794306_32-0"><a href="#cite_note-pmid22794306-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Hormone_therapy">Hormone therapy</h3></summary>
    
<p>The objective behind menopausal hormone therapy is to actively increase the circulating levels of estrogen to control hot flashes and to prevent the long-term effects of the menopause, such as bone resorption and unfavourable changes in blood lipids. The administration of estradiol halts, or reverses atrophic changes that occur due to the loss of endogenous estradiol during the menopause.<span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>

<p>Estrogen promotes endometrial cell growth and in postmenopausal women with an intact uterus, estrogen monotherapy results in continued endometrial development without the physiological secretory changes normally brought on by progesterone. This action is associated with an increased incidence of endometrial hyperplasia and carcinoma. Additional protection with progestogens is therefore important in patients with an intact uterus who receive estrogen therapy. Dydrogesterone counters the proliferative effect of estrogens on the endometrium and ensures the transition to a secretory pattern and cyclical shedding of the endometrium in serial menopausal hormone therapy regimes. Dydrogesterone effectively protects against the ontogenesis of endometrial hyperplasia. Unlike androgenic progestogens, dydrogesterone does not reverse the benefits brought on by estradiol on lipid profiles and carbohydrate metabolism. In a continuous, combined menopausal hormone therapy regimen, dydrogesterone retards the proliferation of the endometrium so that it remains atrophic or inactive.<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Available_forms">Available forms</h3></summary>
    


<p>Dydrogesterone is available in the form of 10<span>&nbsp;</span>mg oral tablets both alone and in combination with estradiol.<span class="mw-ref" id="cite_ref-Muller1998_35-0"><a href="#cite_note-Muller1998-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span><span class="mw-ref" id="cite_ref-ChyeTeng2014_36-0"><a href="#cite_note-ChyeTeng2014-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    



    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>The most commonly reported medication-related adverse reactions in people taking dydrogesterone without an estrogen in clinical trials of indications have included menstrual irregularities, headaches, migraines, nausea, breast tenderness, bloating, and weight gain.<span class="mw-ref" id="cite_ref-MishellKirschbaum1990_10-1"><a href="#cite_note-MishellKirschbaum1990-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Femoston-NHS_11-1"><a href="#cite_note-Femoston-NHS-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> The use of progestins, in particular <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a>, in treating postmenopausal symptoms have been associated with increased risk of blood clots<span class="mw-ref" id="cite_ref-37"><a href="#cite_note-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> and breast cancer in a study carried out by the Women's Health Initiative. While the study did not involve dydrogesterone, it is possible, but not certain, that it too increases these risks.<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<p>Dydrogesterone has been prescribed and used in over 10<span>&nbsp;</span>million pregnancies worldwide. There have been no harmful effects exhibited due to the use of dydrogesterone while pregnant. Dydrogesterone is safe to use during pregnancy only when prescribed and indicated by a medical practitioner.<span class="mw-ref" id="cite_ref-Duphaston_10mg_Film-Coated_Tablets_39-0"><a href="#cite_note-Duphaston_10mg_Film-Coated_Tablets-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Studies have not shown any incidence of decreased fertility due to dydrogesterone at therapeutic dose.<span class="mw-ref" id="cite_ref-Duphaston_10mg_Film-Coated_Tablets_39-1"><a href="#cite_note-Duphaston_10mg_Film-Coated_Tablets-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> The Ames test found no evidence of any potential mutagenic or toxicity properties.<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="margin: 1em auto;">
<caption class="nowrap"> Risk of breast cancer with menopausal hormone therapy in large observational studies (Mirkin, 2018)</caption>
<tbody><tr>
<th class="unsortable">Study</th><th class="unsortable">Therapy</th><th class="unsortable">Hazard ratio (95% <abbr>CI</abbr>)</th></tr>
<tr>
<td rowspan="3">E3N-EPIC: Fournier et al. (2005)</td><td>Estrogen alone</td><td>1.1 (0.8–1.6)</td></tr>
<tr>
<td>Estrogen plus progesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Transdermal estrogen<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Oral estrogen</td><td>0.9 (0.7–1.2)<br>0.9 (0.7–1.2)<br>No events</td></tr>
<tr>
<td>Estrogen plus progestin<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Transdermal estrogen<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Oral estrogen</td><td>1.4 (1.2–1.7)<br>1.4 (1.2–1.7)<br>1.5 (1.1–1.9)</td></tr>
<tr>
<td rowspan="4">E3N-EPIC: Fournier et al. (2008)</td><td>Oral estrogen alone</td><td>1.32 (0.76–2.29)</td></tr>
<tr>
<td>Oral estrogen plus progestogen<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Progesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Dydrogesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Medrogestone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Chlormadinone acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Cyproterone acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a><br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Nomegestrol acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Norethisterone acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></td><td><br>Not analyzed<sup>a</sup><br>0.77 (0.36–1.62)<br>2.74 (1.42–5.29)<br>2.02 (1.00–4.06)<br>2.57 (1.81–3.65)<br>1.62 (0.94–2.82)<br>1.10 (0.55–2.21)<br>2.11 (1.56–2.86)<br>1.48 (1.02–2.16)</td></tr>
<tr>
<td>Transdermal estrogen alone</td><td>1.28 (0.98–1.69)</td></tr>
<tr>
<td>Transdermal estrogen plus progestogen<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Progesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Dydrogesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Medrogestone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Chlormadinone acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Cyproterone acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a><br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Nomegestrol acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Norethisterone acetate<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></td><td><br>1.08 (0.89–1.31)<br>1.18 (0.95–1.48)<br> 2.03 (1.39–2.97)<br>1.48 (1.05–2.09)<br>Not analyzed<sup>a</sup><br>1.52 (1.19–1.96)<br>1.60 (1.28–2.01)<br>Not analyzed<sup>a</sup><br>Not analyzed<sup>a</sup></td></tr>
<tr>
<td rowspan="3">E3N-EPIC: Fournier et al. (2014)</td><td>Estrogen alone</td><td>1.17 (0.99–1.38)</td></tr>
<tr>
<td>Estrogen plus progesterone or dydrogesterone</td><td>1.22 (1.11–1.35)</td></tr>
<tr>
<td>Estrogen plus progestin</td><td>1.87 (1.71–2.04)</td></tr>
<tr>
<td rowspan="2">CECILE: Cordina-Duverger et al. (2013)</td><td>Estrogen alone</td><td>1.19 (0.69–2.04)</td></tr>
<tr>
<td>Estrogen plus progestogen<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Progesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Progestins<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Progesterone derivatives<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>Testosterone derivatives</td><td>1.33 (0.92–1.92)<br>0.80 (0.44–1.43)<br>1.72 (1.11–2.65)<br>1.57 (0.99–2.49)<br>3.35 (1.07–10.4)</td></tr>
<tr class="sortbottom">
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Not analyzed, fewer than 5<span>&nbsp;</span>cases. <b>Sources</b>: See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="margin: 1em auto;">
<caption class="nowrap"> Risk of breast cancer with menopausal hormone therapy by duration in large observational studies (Mirkin, 2018)</caption>
<tbody><tr>
<th class="unsortable">Study</th><th class="unsortable">Therapy</th><th class="unsortable">Hazard ratio (95% <abbr>CI</abbr>)</th></tr>
<tr>
<td rowspan="3">E3N-EPIC: Fournier et al. (2005)<sup>a</sup></td><td>Transdermal estrogen plus progesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;2<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>2–4<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥4<span>&nbsp;</span>years</td><td><br>0.9 (0.6–1.4)<br>0.7 (0.4–1.2)<br>1.2 (0.7–2.0)</td></tr>
<tr>
<td>Transdermal estrogen plus progestin<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;2<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>2–4<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥4<span>&nbsp;</span>years</td><td><br>1.6 (1.3–2.0)<br>1.4 (1.0–1.8)<br>1.2 (0.8–1.7)</td></tr>
<tr>
<td>Oral estrogen plus progestin<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;2<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>2–4<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥4<span>&nbsp;</span>years</td><td><br>1.2 (0.9–1.8)<br>1.6 (1.1–2.3)<br>1.9 (1.2–3.2)</td></tr>
<tr>
<td rowspan="3">E3N-EPIC: Fournier et al. (2008)</td><td>Estrogen plus progesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;2<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>2–4<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>4–6<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥6<span>&nbsp;</span>years</td><td><br>0.71 (0.44–1.14)<br>0.95 (0.67–1.36)<br>1.26 (0.87–1.82)<br>1.22 (0.89–1.67)</td></tr>
<tr>
<td>Estrogen plus dydrogesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;2<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>2–4<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>4–6<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥6<span>&nbsp;</span>years</td><td><br>0.84 (0.51–1.38)<br>1.16 (0.79–1.71)<br>1.28 (0.83–1.99)<br>1.32 (0.93–1.86)</td></tr>
<tr>
<td>Estrogen plus other progestogens<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;2<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>2–4<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>4–6<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥6<span>&nbsp;</span>years</td><td><br>1.36 (1.07–1.72)<br>1.59 (1.30–1.94)<br>1.79 (1.44–2.23)<br>1.95 (1.62–2.35)</td></tr>
<tr>
<td rowspan="2">E3N-EPIC: Fournier et al. (2014)</td><td>Estrogens plus progesterone or dydrogesterone<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;5<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥5<span>&nbsp;</span>years</td><td><br>1.13 (0.99–1.29)<br>1.31 (1.15–1.48)</td></tr>
<tr>
<td>Estrogen plus other progestogens<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>&lt;5<span>&nbsp;</span>years<br><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span>≥5<span>&nbsp;</span>years</td><td><br>1.70 (1.50–1.91)<br>2.02 (1.81–2.26)</td></tr>
<tr class="sortbottom">
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Oral estrogen plus progesterone was not analyzed because there was a low number of women who used this therapy. <b>Sources</b>: See template.</td></tr>
</tbody></table>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    
<p>There is not enough clinical data to support overdose in humans. The maximum dose of dydrogesterone administered to humans to date was 360<span>&nbsp;</span>mg orally, and the medication was found to be well tolerated at this dose. There are no antidotes to overdose, and treatment should be based on symptoms.<span class="mw-ref" id="cite_ref-Duphaston_10mg_Film-Coated_Tablets_39-2"><a href="#cite_note-Duphaston_10mg_Film-Coated_Tablets-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> In acute toxicity trials, the LD<sub>50</sub> doses in rats were in excess of 4,640<span>&nbsp;</span>mg/kg orally.<span class="mw-ref" id="cite_ref-DrugBank_41-0"><a href="#cite_note-DrugBank-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>In menopausal hormone therapy, dydrogesterone is administered together with an estrogen. Therefore, the interaction between dydrogesterone and estrogens has been assessed, and no clinically significant interaction has been observed.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:227px"><img src="../I/m/20α-Dihydrodydrogesterone.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/20%CE%B1-Dihydrodydrogesterone.svg.png" data-file-width="1085" data-file-height="795" data-file-type="drawing" height="165" width="225"><div class="thumbcaption" style="text-align: left">20α-Dihydrodydrogesterone (20α-DHD), the main active form of dydrogesterone.</div></div></div>

<p>Dydrogesterone is a highly selective progestogen, and due to its unique structure, unlike progesterone and many other progestins, binds almost exclusively to the progesterone receptor (PR).<span class="mw-ref" id="cite_ref-SchindlerCampagnoli2003_43-0"><a href="#cite_note-SchindlerCampagnoli2003-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span> The affinity of dydrogesterone for the PR is relatively low at about 16% of that of progesterone.<span class="mw-ref" id="cite_ref-pmid21376746_44-0"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-CabezaHeuze2014_45-0"><a href="#cite_note-CabezaHeuze2014-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> However, <i>in vivo</i>, dydrogesterone is comparatively much more potent by the oral route, with an equivalent dose, in terms of endometrial proliferation, that is 10 to 20<span>&nbsp;</span>times lower than that of progesterone.<span class="mw-ref" id="cite_ref-ColomboFerraboschi2006_46-0"><a href="#cite_note-ColomboFerraboschi2006-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> This is due to pharmacokinetic differences between the two medications, namely improved bioavailability and metabolic stability with dydrogesterone as well as additional progestogenic activity of its metabolites.<span class="mw-ref" id="cite_ref-Schindler2009_47-0"><a href="#cite_note-Schindler2009-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span> Dydrogesterone binds to and activates both of the major isoforms of the PR, the PR-A and PR-B, with a similar selectivity ratio between the two receptors as that of progesterone and with lower efficacy at the receptors relative to progesterone.<span class="mw-ref" id="cite_ref-pmid21376746_44-1"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> The major active metabolite of dydrogesterone, 20α-dihydrodydrogesterone (20α-DHD), has progestogenic activity as well but with greatly decreased potency relative to dydrogesterone.<span class="mw-ref" id="cite_ref-pmid21376746_44-2"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> As with other progestogens, dydrogesterone has functional antiestrogenic effects in certain tissues, for instance in the endometrium, and induces endometrial secretory transformation.<span class="mw-ref" id="cite_ref-pmid16112947_6-6"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>

<p>Dydrogesterone does not bind importantly to the androgen, estrogen, or glucocorticoid receptor.<span class="mw-ref" id="cite_ref-CabezaHeuze2014_45-1"><a href="#cite_note-CabezaHeuze2014-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span><span class="mw-ref" id="cite_ref-pmid21376746_44-3"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> As such, it is devoid of androgenic or antiandrogenic, <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogenic</a> or antiestrogenic, and glucocorticoid or antiglucocorticoid activity.<span class="mw-ref" id="cite_ref-SchindlerCampagnoli2003_43-1"><a href="#cite_note-SchindlerCampagnoli2003-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_6-7"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid21376746_44-4"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Similarly to progesterone however, dydrogesterone binds to the mineralocorticoid receptor and possesses antimineralocorticoid activity, but only weakly so.<span class="mw-ref" id="cite_ref-pmid16112947_6-8"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-pmid21376746_44-5"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Like other progestins but unlike progesterone, which forms sedative neurosteroid metabolites, dydrogesterone is not able to be metabolized in a similar way, and for this reason, is non-sedative.<span class="mw-ref" id="cite_ref-pmid16112947_6-9"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> The medication and 20α-DHD do not inhibit 5α-reductase.<span class="mw-ref" id="cite_ref-pmid21376746_44-6"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Dydrogesterone has been found to inhibit myometrium contractility via an undefined progesterone receptor-independent mechanism <i>in vivo</i> in pregnant rats and <i>in vitro</i> in human tissue at concentrations at which progesterone and other progestogens do not.<span class="mw-ref" id="cite_ref-pmid29981319_48-0"><a href="#cite_note-pmid29981319-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> Affinities of dydrogesterone and related steroids</caption>
<tbody><tr>
<th rowspan="2">Progestogen</th><th colspan="2"><abbr>PR</abbr></th><th colspan="2"><abbr>AR</abbr></th><th colspan="2"><abbr>GR</abbr></th><th><abbr>ERα</abbr></th></tr>
<tr>
<th>K<sub>i</sub> (nM)</th><th><abbr>RBA</abbr> (%)</th><th>K<sub>i</sub> (nM)</th><th><abbr>RBA</abbr> (%)</th><th>K<sub>i</sub> (nM)</th><th><abbr>RBA</abbr> (%)</th><th>K<sub>i</sub> (nM)</th></tr>
<tr>
<td>Dydrogesterone</td><td>125.9</td><td>15.9</td><td>251.2</td><td>10.0</td><td>361.2</td><td>17.5</td><td>&gt;10,000</td></tr>
<tr>
<td>20α-Dihydrodydrogesterone</td><td>125.9</td><td>15.9</td><td>3162.3</td><td>0.8</td><td>3162.3</td><td>2.0</td><td>&gt;10,000</td></tr>
<tr>
<td>Progesterone</td><td>20.0</td><td>100</td><td>25.1</td><td>100</td><td>63.1</td><td>100</td><td>&gt;10,000</td></tr>
<tr class="sortbottom">
<td colspan="8" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Sources:</b> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Atypical_progestogenic_profile">Atypical progestogenic profile</h4></summary>
    
<p>Due to its progestogenic activity, dydrogesterone can produce antigonadotropic effects at sufficient doses in animals.<span class="mw-ref" id="cite_ref-BorisStevenson1966_49-0"><a href="#cite_note-BorisStevenson1966-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span> However, it does not suppress secretion of the gonadotropins, <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> (LH) and follicle-stimulating hormone (FSH), or inhibit ovulation at typical clinical dosages in humans.<span class="mw-ref" id="cite_ref-pmid16112947_6-10"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Tausk1972_13-1"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-Mittal2013_50-0"><a href="#cite_note-Mittal2013-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span> Oral doses of dydrogesterone of 5 to 40<span>&nbsp;</span>mg/day on days 5 to 25 of the cycle fail to suppress ovulation (assessed by urinary <a href="Pregnanediol.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnanediol" title="Pregnanediol">pregnanediol</a> and laparotomy), and one study found that ovulation persisted even in women treated with an oral dosage of as great as 400<span>&nbsp;</span>mg/day (assessed by visual inspection of the ovaries).<span class="mw-ref" id="cite_ref-pmid22078182_51-0"><a href="#cite_note-pmid22078182-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-Tausk1972_13-2"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Likewise, an intramuscular injection of 100<span>&nbsp;</span>mg dydrogesterone in microcrystalline aqueous suspension on the first to third day of the cycle did not interfere with the development of an ovulatory pattern of spontaneous uterine contractions in women.<span class="mw-ref" id="cite_ref-Tausk1972_13-3"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-EskesHein1970_52-0"><a href="#cite_note-EskesHein1970-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> A couple of conflicting studies exist on the issue of ovulation inhibition by dydrogesterone however, with findings of partial or full inhibition of ovulation by oral dydrogesterone.<span class="mw-ref" id="cite_ref-Tausk1972_13-4"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> This included prevention of the mid-cycle LH and FSH peaks and the luteal-phase rise in body temperature and pregnanediol excretion.<span class="mw-ref" id="cite_ref-Tausk1972_13-5"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Nonetheless, the overall consensus among researchers, based on the totality of clinical evidence, is that dydrogesterone does not inhibit ovulation in women.<span class="mw-ref" id="cite_ref-Tausk1972_13-6"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> The apparent inability of dydrogesterone to prevent ovulation is in contrast to all other clinically used progestogens except trengestone, which is closely related to dydrogesterone.<span class="mw-ref" id="cite_ref-pmid22078182_51-1"><a href="#cite_note-pmid22078182-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-HorskyPresl2012_53-0"><a href="#cite_note-HorskyPresl2012-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Similarly to trengestone but also unlike all other clinically used progestogens, dydrogesterone does not have a hyperthermic effect in humans (i.e., it does not increase body temperature).<span class="mw-ref" id="cite_ref-pmid16112947_6-11"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-HorskyPresl2012_53-1"><a href="#cite_note-HorskyPresl2012-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-pmid679688_54-0"><a href="#cite_note-pmid679688-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></p>

<p>It has been said that the lack of ovulation inhibition and hyperthermic effect with retroprogesterone derivatives like dydrogesterone may represent a dissociation of peripheral and central progestogenic activity.<span class="mw-ref" id="cite_ref-Henzl1978_55-0"><a href="#cite_note-Henzl1978-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-Lauritzen1988_56-0"><a href="#cite_note-Lauritzen1988-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span> However, a related retroprogesterone derivative, trengestone, likewise does not inhibit ovulation or produce a hyperthermic effect but rather has an inducing effect on ovulation.<span class="mw-ref" id="cite_ref-HorskyPresl2012_53-2"><a href="#cite_note-HorskyPresl2012-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span></p>

<p>Whereas all other assessed progestins are associated with an increased risk of breast cancer when combined with an estrogen in postmenopausal women, neither oral progesterone nor dydrogesterone are associated with a significantly increased risk of breast cancer (although the risk of breast cancer is non-significantly higher with dydrogesterone).<span class="mw-ref" id="cite_ref-pmid27898258_57-0"><a href="#cite_note-pmid27898258-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span><span class="mw-ref" id="cite_ref-pmid23651281_58-0"><a href="#cite_note-pmid23651281-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-pmid29852797_59-0"><a href="#cite_note-pmid29852797-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> Similarly, like oral progesterone but in contrast to other progestins, dydrogesterone does not appear to further increase the risk of venous thromboembolism when used in combination with an oral estrogen.<span class="mw-ref" id="cite_ref-pmid23835005_60-0"><a href="#cite_note-pmid23835005-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span><span class="mw-ref" id="cite_ref-pmid19565370_61-0"><a href="#cite_note-pmid19565370-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span> Dydrogesterone may also provide inferior endometrial protection relative to other progestins such as <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a> and norethisterone acetate, with a significantly increased risk of endometrial cancer in combination with an estrogen with long-term therapy (&gt;5<span>&nbsp;</span>years).<span class="mw-ref" id="cite_ref-pmid26512775_62-0"><a href="#cite_note-pmid26512775-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span><span class="mw-ref" id="cite_ref-SayeghAwwad2017_63-0"><a href="#cite_note-SayeghAwwad2017-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-pmid19935019_64-0"><a href="#cite_note-pmid19935019-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Other_activity">Other activity</h4></summary>
    
<p>Dydrogesterone weakly stimulates the proliferation of MCF-7 breast cancer cells <i>in vitro</i>, an action that is independent of the classical PRs and is instead mediated via the progesterone receptor membrane component-1 (PGRMC1).<span class="mw-ref" id="cite_ref-pmid23758160_65-0"><a href="#cite_note-pmid23758160-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span> Certain other progestins are also active in this assay, whereas progesterone acts neutrally.<span class="mw-ref" id="cite_ref-pmid23758160_65-1"><a href="#cite_note-pmid23758160-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span> It is unclear if these findings may explain the different risks of breast cancer observed with progesterone, dydrogesterone, and other progestins such as <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a> and <a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">norethisterone</a> in clinical studies.<span class="mw-ref" id="cite_ref-pmid31512725_66-0"><a href="#cite_note-pmid31512725-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Absorption">Absorption</h4></summary>
    
<p>Dydrogesterone and its major metabolite, 20α-DHD, have predictable pharmacokinetics. The single-dose kinetics are linear in the oral dose range of 2.5 to 10<span>&nbsp;</span>mg. The pharmacokinetics do not change during repeated administration of up to 20<span>&nbsp;</span>mg dydrogesterone once daily. Dydrogesterone is readily absorbed with oral administration. The absolute bioavailability of dydrogesterone is on average 28%.<span class="mw-ref" id="cite_ref-Femoston-Label_3-1"><a href="#cite_note-Femoston-Label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> T<sub>max</sub> values vary between 0.5 and 2.5<span>&nbsp;</span>hours.<span class="mw-ref" id="cite_ref-:2_67-0"><a href="#cite_note-:2-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> Steady state is attained after 3<span>&nbsp;</span>days of treatment.<span class="mw-ref" id="cite_ref-Duphaston_10mg_Film-Coated_Tablets_39-3"><a href="#cite_note-Duphaston_10mg_Film-Coated_Tablets-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> The levels of 20α-DHD, which is the main active metabolite, are also found to peak about 1.5<span>&nbsp;</span>hours post-dose.<span class="mw-ref" id="cite_ref-Duphaston_10mg_Film-Coated_Tablets_39-4"><a href="#cite_note-Duphaston_10mg_Film-Coated_Tablets-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>

<p>A single intramuscular injection of 100<span>&nbsp;</span>mg dydrogesterone in microcrystalline aqueous suspension has been found to have a duration of action of 16 to 38<span>&nbsp;</span>days in terms of clinical biological effect in the uterus in women.<span class="mw-ref" id="cite_ref-Tausk1972_13-7"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> This was specifically the time until the onset of withdrawal bleeding in estrogen-treated amenorrheic women.<span class="mw-ref" id="cite_ref-Tausk1972_13-8"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="font-size:small; margin: 1em auto;">
<caption class="nowrap"> <span style="font-family:sans-serif;font-size:105%;color:black;background-color:transparent;;">Parenteral potencies and durations of progestogens</span></caption>
<tbody><tr>
<th>Progestogen</th><th>Form</th><th>Major brand names</th><th>Class</th><th data-sort-type="number"><abbr>TFD</abbr><br><small>(14 days)</small></th><th style="white-space: nowrap;" data-sort-type="number"><abbr>POIC-D</abbr><br><small>(2–3 months)</small></th><th data-sort-type="number"><abbr>CIC-D</abbr><br><small>(month)</small></th><th data-sort-type="number">Duration</th></tr>
<tr>
<td>Algestone acetophenide</td><td>Oil solution</td><td>Perlutal, Topasel, Yectames</td><td>Pregnane</td><td>?</td><td>–</td><td>75–150 mg</td><td>100 mg ≈ 14–32 days</td></tr>
<tr>
<td>Cyproterone acetate</td><td>Oil solution</td><td>Androcur Depot</td><td>Pregnane</td><td>?</td><td>–</td><td>–</td><td>300 mg ≈ 20 days</td></tr>
<tr>
<td>Dydrogesterone<sup>a</sup></td><td>Aqueous suspension</td><td>–</td><td>Retropregnane</td><td>?</td><td>–</td><td>–</td><td>100 mg ≈ 16–38 days</td></tr>
<tr>
<td>Gestonorone caproate</td><td>Oil solution</td><td>Depostat, Primostat</td><td>Norpregnane</td><td>25–50 mg</td><td>–</td><td>–</td><td>25–50 mg ≈ 8–13 days</td></tr>
<tr>
<td>Hydroxyprogesterone acetate<sup>a</sup></td><td>Aqueous suspension</td><td>–</td><td>Pregnane</td><td>350 mg</td><td>–</td><td>–</td><td>150–350 mg ≈ 9–16 days</td></tr>
<tr>
<td>Hydroxyprogesterone caproate</td><td>Oil solution</td><td>Delalutin, Proluton, Makena</td><td>Pregnane</td><td style="white-space: nowrap;">250–500 mg<sup>b</sup></td><td>–</td><td style="white-space: nowrap;">250–500 mg</td><td>65–500 mg ≈ 5–21 days</td></tr>
<tr>
<td>Levonorgestrel butanoate<sup>a</sup></td><td>Aqueous suspension</td><td>–</td><td>Gonane</td><td>?</td><td>–</td><td>–</td><td>5–50 mg ≈ 3–6 months</td></tr>
<tr>
<td>Lynestrenol phenylpropionate<sup>a</sup></td><td>Oil solution</td><td>–</td><td>Estrane</td><td>?</td><td>–</td><td>–</td><td>50–100 mg ≈ 14–30 days</td></tr>
<tr>
<td><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></td><td>Aqueous suspension</td><td>Depo-Provera</td><td>Pregnane</td><td>50–100 mg</td><td>150 mg</td><td>25 mg</td><td style="white-space: nowrap;">50–150 mg ≈ 14–50+ days</td></tr>
<tr>
<td>Megestrol acetate</td><td>Aqueous suspension</td><td>Mego-E</td><td>Pregnane</td><td>?</td><td>–</td><td>25 mg</td><td>25 mg ≈ &gt;14 days<sup>c</sup></td></tr>
<tr>
<td>Norethisterone enanthate</td><td>Oil solution</td><td>Noristerat, Mesigyna</td><td>Estrane</td><td>100–200 mg</td><td>200 mg</td><td>50 mg</td><td>50–200 mg ≈ 11–52 days</td></tr>
<tr>
<td>Oxogestone phenylpropionate<sup>a</sup></td><td>Oil solution</td><td>–</td><td>Norpregnane</td><td>?</td><td>–</td><td>–</td><td>100 mg ≈ 19–20 days</td></tr>
<tr>
<td rowspan="2">Progesterone</td><td>Oil solution</td><td>Progestaject, Gestone, Strone</td><td>Pregnane</td><td>200 mg<sup>b</sup></td><td>–</td><td>–</td><td>25–350 mg ≈ 2–6 days</td></tr>
<tr>
<td>Aqueous suspension</td><td>Agolutin Depot</td><td>Pregnane</td><td>50–200 mg</td><td>–</td><td>–</td><td>50–300 mg ≈ 7–14 days</td></tr>
<tr class="sortbottom">
<td colspan="9" style="width: 1px; background-color:#eaecf0; background-color:#eaecf0; text-align: center;"><b>Note:</b> All by intramuscular or subcutaneous injection. All are synthetic except for <a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone"><abbr>P4</abbr></a>, which is bioidentical. <abbr>P4</abbr> production during the luteal phase is ~25<span>&nbsp;</span>(15–50)<span>&nbsp;</span>mg/day. The <abbr>OID</abbr> of OHPC is 250 to 500<span>&nbsp;</span>mg/month. <b>Footnotes:</b> <sup>a</sup> = Never marketed by this route. <sup>b</sup> = In divided doses (2 × 125 or 250<span>&nbsp;</span>mg for <abbr>OHPC</abbr>, 10 × 20<span>&nbsp;</span>mg for <abbr>P4</abbr>). <sup>c</sup> = Half-life is ~14 days. <b>Sources:</b> <i>Main:</i> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Distribution">Distribution</h4></summary>
    
<p>The plasma protein binding of dydrogesterone and 20α-DHD are unknown. Based on the plasma protein binding of other progestins however, they are probably bound to <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a> and not to sex hormone-binding globulin or corticosteroid-binding globulin.<span class="mw-ref" id="cite_ref-FRCOG2015_5-1"><a href="#cite_note-FRCOG2015-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-pmid16112947_6-12"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Metabolism">Metabolism</h4></summary>
    
<p>The metabolism of dydrogesterone occurs in the liver.<span class="mw-ref" id="cite_ref-Carp2015_68-0"><a href="#cite_note-Carp2015-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> It is virtually completely metabolized.<span class="mw-ref" id="cite_ref-Carp2015_68-1"><a href="#cite_note-Carp2015-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> The primary metabolic pathway is the hydrogenation of the 20-keto group mainly by AKR1C1 and to a lesser extent AKR1C3, resulting in 20α-DHD. This active metabolite is a progestogen similarly to dydrogesterone, albeit with much lower potency.<span class="mw-ref" id="cite_ref-BeraničGobec2011_8-2"><a href="#cite_note-BeraničGobec2011-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> With oral administration of dydrogesterone, circulating levels of 20α-DHD are substantially higher than those of dydrogesterone.<span class="mw-ref" id="cite_ref-pmid21376746_44-7"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> The ratios of 20α-DHD to dydrogesterone in terms of peak levels and area-under-the-curve (AUC) levels have been found to be 25:1 and 40:1, respectively.<span class="mw-ref" id="cite_ref-pmid21376746_44-8"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> For these reasons, despite the lower relative progestogenic potency of 20α-DHD, dydrogesterone may act as a prodrug of this metabolite.<span class="mw-ref" id="cite_ref-pmid21376746_44-9"><a href="#cite_note-pmid21376746-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>

<p>The metabolism of dydrogesterone differs from progesterone.<span class="mw-ref" id="cite_ref-Tausk1972_13-9"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Whereas the major metabolite of progesterone is <a href="Pregnanediol.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnanediol" title="Pregnanediol">pregnanediol</a>, the corresponding derivative of dydrogesterone, retropregnanediol, cannot be detected in urine with oral administration of dydrogesterone.<span class="mw-ref" id="cite_ref-Tausk1972_13-10"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> All of the metabolites of dydrogesterone retain the 4,6-diene-3-one structure and are metabolically stable. As such, similarly to progesterone, dydrogesterone does not undergo aromatization.</p>

<p>The mean elimination half-lives of dydrogesterone and 20α-DHD are in the ranges of 5 to 7<span>&nbsp;</span>hours and 14 to 17<span>&nbsp;</span>hours, respectively.<span class="mw-ref" id="cite_ref-BińkowskaWoroń2015_9-2"><a href="#cite_note-BińkowskaWoroń2015-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Excretion">Excretion</h4></summary>
    
<p>Dydrogesterone and its metabolites are excreted predominantly in urine. Total clearance of plasma is at a rate of 6.4<span>&nbsp;</span>L/min. Within 72<span>&nbsp;</span>hours, excretion is virtually complete. 20α-DHD is preponderantly present in the urine as a conjugate of <a href="Glucuronic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glucuronic_acid" title="Glucuronic acid">glucuronic acid</a>. Approximately 85% of the oral dose is successfully removed from the body within 24<span>&nbsp;</span>hours. Around 90% of excreted material is 20α-DHD.<span class="mw-ref" id="cite_ref-Tausk1972_13-11"><a href="#cite_note-Tausk1972-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Miscellaneous">Miscellaneous</h4></summary>
    
<p>The pharmacokinetics of dydrogesterone have been reviewed.<span class="mw-ref" id="cite_ref-pmid16112947_6-13"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Springer2013_69-0"><a href="#cite_note-Springer2013-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    

<div class="thumb tright"><div class="thumbinner" style="width:227px"><img src="../I/m/Progesterone_and_dydrogesterone_3D_chemical_structures_comparison.png" tppabs="https://ptable.com/wiki/compounds/I/m/Progesterone_and_dydrogesterone_3D_chemical_structures_comparison.png" data-file-width="1733" data-file-height="2800" data-file-type="bitmap" height="364" width="225"><div class="thumbcaption" style="text-align: left">A 3D schematic representation of the chemical structures of progesterone (top) and dydrogesterone (bottom), showing the retrosteroid spatial configuration of dydrogesterone.<span class="mw-ref" id="cite_ref-pmid16112947_6-14"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-SchindlerCampagnoli2003_43-2"><a href="#cite_note-SchindlerCampagnoli2003-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></div></div></div>

<p>Dydrogesterone, also known as 6-dehydro-9β,10α-progesterone or as 9β,10α-pregna-4,6-diene-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone and retroprogesterone (9β,10α-progesterone).<span class="mw-ref" id="cite_ref-Elks2014_1-1"><a href="#cite_note-Elks2014-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-2"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Retroprogesterone derivatives like dydrogesterone are analogues of progesterone in which the <a href="Hydrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrogen" title="Hydrogen">hydrogen</a> atom at the 9th carbon has been switched from the α-position (below the plane) to the β-position (above the plane) and the <a href="Methyl_group.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyl_group" title="Methyl group">methyl group</a> at the 10th carbon has been switched from the β-position to the α-position.<span class="mw-ref" id="cite_ref-HorskyPresl2012_53-3"><a href="#cite_note-HorskyPresl2012-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> This reversed configuration in dydrogesterone results in a "bent" spatial geometry in which the plane of rings A and B is orientated at a 60° angle below the rings C and D.<span class="mw-ref" id="cite_ref-pmid16112947_6-15"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Dydrogesterone also has an additional double bond between the C6 and C7 positions (4,6-dien-3-one configuration).<span class="mw-ref" id="cite_ref-Elks2014_1-2"><a href="#cite_note-Elks2014-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-3"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> While its chemical structure is close to that of progesterone, these changes result in dydrogesterone having improved oral activity and metabolic stability, among other differences, in comparison to progesterone.<span class="mw-ref" id="cite_ref-pmid16112947_6-16"><a href="#cite_note-pmid16112947-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-SchindlerCampagnoli2003_43-3"><a href="#cite_note-SchindlerCampagnoli2003-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Analogues">Analogues</h3></summary>
    
<p>Other retroprogesterone derivatives, and analogues of dydrogesterone, include trengestone (1,6-didehydro-6-chlororetroprogesterone) and Ro 6-3129 (16α-ethylthio-6-dehydroretroprogesterone).<span class="mw-ref" id="cite_ref-Elks2014_1-3"><a href="#cite_note-Elks2014-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-4"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Synthesis">Synthesis</h3></summary>
    
<p>Dydrogesterone is synthesized and manufactured by treatment of progesterone with ultraviolet light exposure.<span class="mw-ref" id="cite_ref-SchindlerCampagnoli2003_43-4"><a href="#cite_note-SchindlerCampagnoli2003-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>

<p>Chemical syntheses of dydrogesterone have been published.<span class="mw-ref" id="cite_ref-Springer2013_69-1"><a href="#cite_note-Springer2013-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Dydrogesterone is a progestin which was first synthesized by Duphar in the 1950s and was first introduced to the market in 1961. It is unique, being the only retrosteroid that is commercially available and its molecular structure is closely related to that of natural progesterone,<span class="mw-ref" id="cite_ref-70"><a href="#cite_note-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span> but it has enhanced oral bioavailability. It is estimated that during the period from 1977 to 2005<span class="mw-ref" id="cite_ref-71"><a href="#cite_note-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span> around 38 million women were treated with dydrogesterone and that fetuses were exposed to dydrogesterone <i>in utero</i> in more than 10 million pregnancies. It has been approved in more than 100 countries worldwide. It is commercially marketed under the brand name Duphaston and manufactured by Abbott after it took over Solvay Pharmaceuticals. Dydrogesterone was first introduced, by Duphar, as Duphaston in the United Kingdom in 1961.<span class="mw-ref" id="cite_ref-Publishing2013_14-3"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Subsequently, it was introduced in the United States as Duphaston and Gynorest in 1962 and 1968, respectively.<span class="mw-ref" id="cite_ref-Publishing2013_14-4"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Duphaston was removed from the United States market in 1979,<span class="mw-ref" id="cite_ref-Freedman1986_72-0"><a href="#cite_note-Freedman1986-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span> and Gynorest is also no longer available in the United States.<span class="mw-ref" id="cite_ref-FDA_73-0"><a href="#cite_note-FDA-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Generic_names">Generic names</h3></summary>
    
<p><i>Dydrogesterone</i> is the generic name of the drug and its <abbr>INN</abbr>, <abbr>USAN</abbr>, and <abbr>BAN</abbr>, while <i>dydrogestérone</i> is its <abbr>DCF</abbr> and <i>didrogesterone</i> is its <abbr>DCIT</abbr>.<span class="mw-ref" id="cite_ref-Elks2014_1-4"><a href="#cite_note-Elks2014-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-5"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Publishing2013_14-5"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_74-0"><a href="#cite_note-Drugs.com-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> It was also originally known as <i>isopregnenone</i>.<span class="mw-ref" id="cite_ref-Elks2014_1-5"><a href="#cite_note-Elks2014-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-6"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Publishing2013_14-6"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_74-1"><a href="#cite_note-Drugs.com-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> Dydrogesterone has also been referred to as <i>retroprogesterone</i>, but should not be confused with retroprogesterone.<span class="mw-ref" id="cite_ref-GöretzlehnerLauritzen2012_75-0"><a href="#cite_note-GöretzlehnerLauritzen2012-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>Dydrogesterone is marketed mainly under the brand names Duphaston (alone) and Femoston (in combination with estradiol).<span class="mw-ref" id="cite_ref-Drugs.com_74-2"><a href="#cite_note-Drugs.com-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-7"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It also is or has been marketed alone under the brand names Dabroston, Dufaston, Duvaron, Gestatron, Gynorest, Prodel, Retrone, and Terolut and in combination with estradiol under the brand names Climaston, Femaston, and Femphascyl.<span class="mw-ref" id="cite_ref-Drugs.com_74-3"><a href="#cite_note-Drugs.com-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-8"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014_1-6"><a href="#cite_note-Elks2014-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Publishing2013_14-7"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Availability">Availability</h3></summary>
    
<p>Dydrogesterone is available widely throughout the world.<span class="mw-ref" id="cite_ref-Drugs.com_74-4"><a href="#cite_note-Drugs.com-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-9"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is marketed in the United Kingdom, Ireland, South Africa, and Australia, but not in the United States, Canada, or New Zealand.<span class="mw-ref" id="cite_ref-Drugs.com_74-5"><a href="#cite_note-Drugs.com-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-10"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> The medication was previously available in the United States,<span class="mw-ref" id="cite_ref-Publishing2013_14-8"><a href="#cite_note-Publishing2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> but has since been discontinued in this country.<span class="mw-ref" id="cite_ref-Manu2000_15-1"><a href="#cite_note-Manu2000-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> Dydrogesterone is also available in elsewhere in Europe, as well as in Central and South America, Asia, and North Africa.<span class="mw-ref" id="cite_ref-Drugs.com_74-6"><a href="#cite_note-Drugs.com-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_2-11"><a href="#cite_note-IndexNominum2000-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<ul><li>Estradiol/dydrogesterone</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References_2">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Elks2014-1"> <span id="mw-reference-text-cite_note-Elks2014-1" class="mw-reference-text"><cite id="CITEREFJ._Elks2014" class="citation book cs1">J. Elks (14 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA474  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA474'" tppabs="https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA474" class="external text external"><i>The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies</i></a>. Springer. pp.<span>&nbsp;</span>474–. ISBN<span>&nbsp;</span><bdi>978-1-4757-2085-3</bdi>.</cite></span></li><li id="cite_note-IndexNominum2000-2"> <span id="mw-reference-text-cite_note-IndexNominum2000-2" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA378  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA378'" tppabs="https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA378" class="external text external"><i>Index Nominum 2000: International Drug Directory</i></a>. Taylor &amp; Francis. January 2000. pp.<span>&nbsp;</span>378–. ISBN<span>&nbsp;</span><bdi>978-3-88763-075-1</bdi>.</cite></span></li><li id="cite_note-Femoston-Label-3"> <span id="mw-reference-text-cite_note-Femoston-Label-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medicines.ie/printfriendlydocument.aspx?documentid=5165&companyid=3070  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicines.ie/printfriendlydocument.aspx?documentid=5165&companyid=3070'" tppabs="http://www.medicines.ie/printfriendlydocument.aspx?documentid=5165&companyid=3070" class="external text external">"Femoston 2/10mg film-coated tablets"</a>. <i>medicines.ie Ireland</i>.</cite></span></li><li id="cite_note-Schindler2015-4"> <span id="mw-reference-text-cite_note-Schindler2015-4" class="mw-reference-text"><cite id="CITEREFSchindler2015" class="citation journal cs1">Schindler, Adolf E. (2015). "Pharmacology of Progestogens": 33–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-319-14385-9_2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-319-14385-9_2'" tppabs="https://doi.org/10.1007%2F978-3-319-14385-9_2" class="external text external">10.1007/978-3-319-14385-9_2</a>.</cite> <span class="cs1-hidden-error error citation-comment">Cite journal requires <code class="cs1-code"><span>|</span>journal=</code> (help)</span></span></li><li id="cite_note-FRCOG2015-5"> <span id="mw-reference-text-cite_note-FRCOG2015-5" class="mw-reference-text"><cite id="CITEREFHoward_J.A._Carp,_MB,_BS,_FRCOG2015" class="citation book cs1">Howard J.A. Carp, MB, BS, FRCOG (9 April 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=Ik8SCAAAQBAJ&pg=PA33  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Ik8SCAAAQBAJ&pg=PA33'" tppabs="https://books.google.com/books?id=Ik8SCAAAQBAJ&pg=PA33" class="external text external"><i>Progestogens in Obstetrics and Gynecology</i></a>. Springer. pp.<span>&nbsp;</span>33, 38. ISBN<span>&nbsp;</span><bdi>978-3-319-14385-9</bdi>.</cite></span></li><li id="cite_note-pmid16112947-6"> <span id="mw-reference-text-cite_note-pmid16112947-6" class="mw-reference-text"><cite id="CITEREFKuhl2005" class="citation journal cs1">Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". <i>Climacteric</i>. 8 Suppl 1: 3–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F13697130500148875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F13697130500148875'" tppabs="https://doi.org/10.1080%2F13697130500148875" class="external text external">10.1080/13697130500148875</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16112947  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16112947'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16112947" class="external text external">16112947</a>.</cite></span></li><li id="cite_note-OlbrichWeigl2016-7"> <span id="mw-reference-text-cite_note-OlbrichWeigl2016-7" class="mw-reference-text"><cite id="CITEREFOlbrichWeiglKahlerMihara2016" class="citation journal cs1">Olbrich, Matthias; Weigl, Kevin; Kahler, Elke; Mihara, Katsuhiro (2016). "Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes". <i>Xenobiotica</i>. <b>46</b> (10): 868–874. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F00498254.2015.1134852  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F00498254.2015.1134852'" tppabs="https://doi.org/10.3109%2F00498254.2015.1134852" class="external text external">10.3109/00498254.2015.1134852</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0049-8254  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0049-8254'" tppabs="https://www.worldcat.org/issn/0049-8254" class="external text external">0049-8254</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26796435  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26796435'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26796435" class="external text external">26796435</a>.</cite></span></li><li id="cite_note-BeraničGobec2011-8"> <span id="mw-reference-text-cite_note-BeraničGobec2011-8" class="mw-reference-text"><cite id="CITEREFBeraničGobecRižner2011" class="citation journal cs1">Beranič, N.; Gobec, S.; Rižner, T. Lanišnik (2011). "Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3". <i>Chemico-Biological Interactions</i>. <b>191</b> (1–3): 227–233. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.cbi.2010.12.012  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.cbi.2010.12.012'" tppabs="https://doi.org/10.1016%2Fj.cbi.2010.12.012" class="external text external">10.1016/j.cbi.2010.12.012</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0009-2797  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0009-2797'" tppabs="https://www.worldcat.org/issn/0009-2797" class="external text external">0009-2797</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21182831  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21182831'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21182831" class="external text external">21182831</a>.</cite></span></li><li id="cite_note-BińkowskaWoroń2015-9"> <span id="mw-reference-text-cite_note-BińkowskaWoroń2015-9" class="mw-reference-text"><cite id="CITEREFBińkowskaWoroń2015" class="citation journal cs1">Bińkowska, Małgorzata; Woroń, Jarosław (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498031'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498031" class="external text external">"Progestogens in menopausal hormone therapy"</a>. <i>Menopausal Review</i>. <b>14</b> (2): 134–143. doi:<a href="javascript:if(confirm('https://doi.org/10.5114%2Fpm.2015.52154  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.5114%2Fpm.2015.52154'" tppabs="https://doi.org/10.5114%2Fpm.2015.52154" class="external text external">10.5114/pm.2015.52154</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1643-8876  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1643-8876'" tppabs="https://www.worldcat.org/issn/1643-8876" class="external text external">1643-8876</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498031'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498031" class="external text external">4498031</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26327902  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26327902'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26327902" class="external text external">26327902</a>.</cite></span></li><li id="cite_note-MishellKirschbaum1990-10"> <span id="mw-reference-text-cite_note-MishellKirschbaum1990-10" class="mw-reference-text"><cite id="CITEREFDaniel_R._MishellThomas_H._KirschbaumC._Paul_Morrow" class="citation book cs1">Daniel R. Mishell; Thomas H. Kirschbaum; C. Paul Morrow. <a href="javascript:if(confirm('https://books.google.com/books?id=0jYWNtrtD8MC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0jYWNtrtD8MC'" tppabs="https://books.google.com/books?id=0jYWNtrtD8MC" class="external text external"><i>1990 The Year Book of Obstetrics and Gynecology</i></a>. Year Book Medical.</cite></span></li><li id="cite_note-Femoston-NHS-11"> <span id="mw-reference-text-cite_note-Femoston-NHS-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nhs.uk/Medicine-Guides/Pages/MedicineSideEffects.aspx?condition=Hormone%20replacement%20therapy&medicine=Dydrogesterone/Estradiol  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nhs.uk/Medicine-Guides/Pages/MedicineSideEffects.aspx?condition=Hormone%20replacement%20therapy&medicine=Dydrogesterone/Estradiol'" tppabs="http://www.nhs.uk/Medicine-Guides/Pages/MedicineSideEffects.aspx?condition=Hormone%20replacement%20therapy&medicine=Dydrogesterone/Estradiol" class="external text external">"Dydrogesterone/Estradiol (Generic Femoston 1/10mg tablets)"</a>. <i>National Health Service (England)</i>.</cite></span></li><li id="cite_note-pmid19969432-12"> <span id="mw-reference-text-cite_note-pmid19969432-12" class="mw-reference-text"><cite id="CITEREFSchindler_AE2009" class="citation journal cs1">Schindler AE (6 December 2009). "Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium". <i>Maturitas</i>. 65 Suppl 1: S3–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.10.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.10.011'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.10.011" class="external text external">10.1016/j.maturitas.2009.10.011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19969432  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19969432'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19969432" class="external text external">19969432</a>.</cite></span></li><li id="cite_note-Tausk1972-13"> <span id="mw-reference-text-cite_note-Tausk1972-13" class="mw-reference-text"><cite class="citation journal cs1">"Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs". <i>International Encyclopaedia of Pharmacology and Therapeutics</i>. <b>48</b>: 19, 220, 278, 285, 481. 1972.</cite></span></li><li id="cite_note-Publishing2013-14"> <span id="mw-reference-text-cite_note-Publishing2013-14" class="mw-reference-text"><cite id="CITEREFWilliam_Andrew_Publishing2013" class="citation book cs1">William Andrew Publishing (22 October 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1411  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1411'" tppabs="https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1411" class="external text external"><i>Pharmaceutical Manufacturing Encyclopedia, 3rd Edition</i></a>. Elsevier. pp.<span>&nbsp;</span>1411–. ISBN<span>&nbsp;</span><bdi>978-0-8155-1856-3</bdi>.</cite></span></li><li id="cite_note-Manu2000-15"> <span id="mw-reference-text-cite_note-Manu2000-15" class="mw-reference-text"><cite id="CITEREFPeter_Manu2000" class="citation book cs1">Peter Manu (28 July 2000). <a href="javascript:if(confirm('https://books.google.com/books?id=WK3W5WDR5KgC&pg=PA235  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WK3W5WDR5KgC&pg=PA235'" tppabs="https://books.google.com/books?id=WK3W5WDR5KgC&pg=PA235" class="external text external"><i>The Pharmacotherapy of Common Functional Syndromes: Evidence-Based Guidelines for Primary Care Practice</i></a>. CRC Press. pp.<span>&nbsp;</span>235–. ISBN<span>&nbsp;</span><bdi>978-0-7890-0588-5</bdi>. <q>The drug is not available for clinical use in the United States.</q></cite></span></li><li id="cite_note-pmid14667985-16"> <span id="mw-reference-text-cite_note-pmid14667985-16" class="mw-reference-text"><cite id="CITEREFCoelingh_Bennink_HJBoerrigter_PJ.2003" class="citation journal cs1">Coelingh Bennink HJ; Boerrigter PJ. (2003). "Use of dydrogesterone as a progestogen for oral contraception". <i>Steroids</i>. <b>68</b> (10–13): 927–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.steroids.2003.07.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.steroids.2003.07.006'" tppabs="https://doi.org/10.1016%2Fj.steroids.2003.07.006" class="external text external">10.1016/j.steroids.2003.07.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14667985  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14667985'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14667985" class="external text external">14667985</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFBalasch_JVanrell_JAMárquez_MBurzaco_I1982" class="citation journal cs1">Balasch J; Vanrell JA; Márquez M; Burzaco I; González-Merlo J. (June 1982). "Dehydrogesterone versus vaginal progesterone in the treatment of the endometrial luteal phase deficiency". <i>Fertil Steril</i>. <b>37</b> (6): 751–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0015-0282%2816%2946333-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0015-0282%2816%2946333-8'" tppabs="https://doi.org/10.1016%2FS0015-0282%2816%2946333-8" class="external text external">10.1016/S0015-0282(16)46333-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7084497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7084497'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7084497" class="external text external">7084497</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clinicaltrials.gov/ct2/show/NCT01178931  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clinicaltrials.gov/ct2/show/NCT01178931'" tppabs="https://clinicaltrials.gov/ct2/show/NCT01178931" class="external text external">"Dydrogesterone Versus Intravaginal Progesterone in the Luteal Phase Support"</a>. <i>ClinicalTrials.gov</i>.</cite></span></li><li id="cite_note-pmid20005647-19"> <span id="mw-reference-text-cite_note-pmid20005647-19" class="mw-reference-text"><cite id="CITEREFPandian_RU2009" class="citation journal cs1">Pandian RU (2009). "Dydrogesterone in threatened miscarriage: a Malaysian experience". <i>Maturitas</i>. <b>65</b> (1): S47–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.11.016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.11.016'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.11.016" class="external text external">10.1016/j.maturitas.2009.11.016</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20005647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20005647'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20005647" class="external text external">20005647</a>.</cite></span></li><li id="cite_note-:0-20"> <span id="mw-reference-text-cite_note-:0-20" class="mw-reference-text"><cite id="CITEREFCarp_H2015" class="citation journal cs1">Carp H (2015). "A systematic review of dydrogesterone for the treatment of recurrent miscarriage". <i>Gynecol. Endocrinol</i>. <b>31</b> (6): 1–9. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F09513590.2015.1006618  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F09513590.2015.1006618'" tppabs="https://doi.org/10.3109%2F09513590.2015.1006618" class="external text external">10.3109/09513590.2015.1006618</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25765519  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25765519'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25765519" class="external text external">25765519</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFTabaste_JLServaud_MSteiner_EDabir_P1984" class="citation journal cs1">Tabaste JL; Servaud M; Steiner E; Dabir P; Bene B; Pouzet M. (1984). "Action of dydrogesterone in postpubertal menstruation disorders". <i>Rev Fr Gynecol Obstet</i>. <b>79</b> (1): 19–20, 23–5. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6531584  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6531584'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6531584" class="external text external">6531584</a>.</cite></span></li><li id="cite_note-ReferenceA-22"> <span id="mw-reference-text-cite_note-ReferenceA-22" class="mw-reference-text"><cite id="CITEREFDennerstein_LMorse_CGotts_GBrown_J1986" class="citation journal cs1">Dennerstein L; Morse C; Gotts G; Brown J; Smith M; Oats J; Burrows G. (1986). "Treatment of premenstrual syndrome. A double-blind trial of dydrogesterone". <i>J Affect Disord</i>. <b>11</b> (3): 199–205. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0165-0327%2886%2990070-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0165-0327%2886%2990070-4'" tppabs="https://doi.org/10.1016%2F0165-0327%2886%2990070-4" class="external text external">10.1016/0165-0327(86)90070-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2951407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2951407'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2951407" class="external text external">2951407</a>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFJohnston_WI.1976" class="citation journal cs1">Johnston WI. (1976). "Dydrogesterone and endometriosis". <i>Br J Obstet Gynaecol</i>. <b>83</b> (1): 77–80. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1471-0528.1976.tb00734.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1471-0528.1976.tb00734.x'" tppabs="https://doi.org/10.1111%2Fj.1471-0528.1976.tb00734.x" class="external text external">10.1111/j.1471-0528.1976.tb00734.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1252380  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1252380'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1252380" class="external text external">1252380</a>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nhs.uk/Medicine-Guides/Pages/MedicineOverview.aspx?condition=Hormone%20replacement%20therapy&medicine=Dydrogesterone/Estradiol  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nhs.uk/Medicine-Guides/Pages/MedicineOverview.aspx?condition=Hormone%20replacement%20therapy&medicine=Dydrogesterone/Estradiol'" tppabs="http://www.nhs.uk/Medicine-Guides/Pages/MedicineOverview.aspx?condition=Hormone%20replacement%20therapy&medicine=Dydrogesterone/Estradiol" class="external text external">"Dydrogesterone/Estradiol Hormone Replacement Therapy"</a>. <i>National Health Service</i>.</cite></span></li><li id="cite_note-pmid17943543-25"> <span id="mw-reference-text-cite_note-pmid17943543-25" class="mw-reference-text"><cite id="CITEREFTrivedi_PSelvaraj_KMahapatra_PDSrivastava_S2007" class="citation journal cs1">Trivedi P; Selvaraj K; Mahapatra PD; Srivastava S; Malik S. (2007). "Effective post-laparoscopic treatment of endometriosis with dydrogesterone". <i>Gynecol. Endocrinol</i>. <b>23</b> (Suppl 1): 73–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F09513590701669583  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F09513590701669583'" tppabs="https://doi.org/10.1080%2F09513590701669583" class="external text external">10.1080/09513590701669583</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17943543  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17943543'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17943543" class="external text external">17943543</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFPanay_NPritsch_MAlt_J.2007" class="citation journal cs1">Panay N; Pritsch M; Alt J. (2007). "Cyclical dydrogesterone in secondary amenorrhea: results of a double-blind, placebo-controlled, randomized study". <i>Gynecol Endocrinol</i>. <b>23</b> (11): 611–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F09513590701582554  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F09513590701582554'" tppabs="https://doi.org/10.1080%2F09513590701582554" class="external text external">10.1080/09513590701582554</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17891596  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17891596'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17891596" class="external text external">17891596</a>.</cite></span></li><li id="cite_note-pmid19945806-27"> <span id="mw-reference-text-cite_note-pmid19945806-27" class="mw-reference-text"><cite id="CITEREFSchweppe_KW.2009" class="citation journal cs1">Schweppe KW. (2009). "The place of dydrogesterone in the treatment of endometriosis and adenomyosis". <i>Maturitas</i>. <b>65</b> (Suppl 1): S23–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.11.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.11.011'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.11.011" class="external text external">10.1016/j.maturitas.2009.11.011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19945806  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19945806'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19945806" class="external text external">19945806</a>.</cite></span></li><li id="cite_note-pmid12227885-28"> <span id="mw-reference-text-cite_note-pmid12227885-28" class="mw-reference-text"><cite id="CITEREFWinklerSchindlerBrinkmannEbert2001" class="citation journal cs1">Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C (2001). "Cyclic progestin therapy for the management of mastopathy and mastodynia". <i>Gynecol. Endocrinol</i>. 15 Suppl 6: 37–43. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2Fgye.15.s6.37.43  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2Fgye.15.s6.37.43'" tppabs="https://doi.org/10.1080%2Fgye.15.s6.37.43" class="external text external">10.1080/gye.15.s6.37.43</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12227885  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12227885'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12227885" class="external text external">12227885</a>.</cite></span></li><li id="cite_note-pmid25622239-29"> <span id="mw-reference-text-cite_note-pmid25622239-29" class="mw-reference-text"><cite id="CITEREFTomicTomicKlaicKasum2014" class="citation journal cs1">Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K (2014). "Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial". <i>Eur J Obstet Gynecol Reprod Biol</i>. <b>186</b> (1): 49–53. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejogrb.2014.11.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejogrb.2014.11.002'" tppabs="https://doi.org/10.1016%2Fj.ejogrb.2014.11.002" class="external text external">10.1016/j.ejogrb.2014.11.002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25622239  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25622239'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25622239" class="external text external">25622239</a>.</cite></span></li><li id="cite_note-BarbosaValadares2018-30"> <span id="mw-reference-text-cite_note-BarbosaValadares2018-30" class="mw-reference-text"><cite id="CITEREFBarbosaValadaresBarbosaAmaral2018" class="citation journal cs1">Barbosa, Marina Wanderley Paes; Valadares, Natália Paes Barbosa; Barbosa, Antônio César Paes; Amaral, Adelino Silva; Iglesias, José Rubens; Nastri, Carolina Oliveira; Martins, Wellington de Paula; Nakagawa, Hitomi Miura (2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982562'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982562" class="external text external">"Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis"</a>. <i>JBRA Assisted Reproduction</i>. doi:<a href="javascript:if(confirm('https://doi.org/10.5935%2F1518-0557.20180018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.5935%2F1518-0557.20180018'" tppabs="https://doi.org/10.5935%2F1518-0557.20180018" class="external text external">10.5935/1518-0557.20180018</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1518-0557  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1518-0557'" tppabs="https://www.worldcat.org/issn/1518-0557" class="external text external">1518-0557</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982562'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982562" class="external text external">5982562</a></span>.</cite></span></li><li id="cite_note-GriesingerBlockeel2018-31"> <span id="mw-reference-text-cite_note-GriesingerBlockeel2018-31" class="mw-reference-text"><cite id="CITEREFGriesingerBlockeelT._SukhikhPatki2018" class="citation journal cs1">Griesinger, Georg; Blockeel, Christophe; T. Sukhikh, Gennady; Patki, Ameet; Dhorepatil, Bharati; Yang, Dong-Zi; Chen, Zi-Jiang; Kahler, Elke; Pexman-Fieth, Claire; Tournaye, Herman (2018). <a href="javascript:if(confirm('https://doi.org/10.1093/humrep/dey306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/humrep/dey306'" tppabs="https://doi.org/10.1093/humrep/dey306" class="external text external">"Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial"</a>. <i>Human Reproduction</i>. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Fhumrep%2Fdey306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fhumrep%2Fdey306'" tppabs="https://doi.org/10.1093%2Fhumrep%2Fdey306" class="external text external">10.1093/humrep/dey306</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0268-1161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0268-1161'" tppabs="https://www.worldcat.org/issn/0268-1161" class="external text external">0268-1161</a>.</cite></span></li><li id="cite_note-pmid22794306-32"> <span id="mw-reference-text-cite_note-pmid22794306-32" class="mw-reference-text"><cite id="CITEREFCarp_H2012" class="citation journal cs1">Carp H (2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297" class="external text external">"A systematic review of dydrogesterone for the treatment of threatened miscarriage"</a>. <i>Gynecol. Endocrinol</i>. <b>28</b> (12): 983–90. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F09513590.2012.702875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F09513590.2012.702875'" tppabs="https://doi.org/10.3109%2F09513590.2012.702875" class="external text external">10.3109/09513590.2012.702875</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297" class="external text external">3518297</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22794306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22794306'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22794306" class="external text external">22794306</a>.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite id="CITEREFSantenAllredArdoinArcher2010" class="citation journal cs1">Santen, Richard J.; Allred, D. Craig; Ardoin, Stacy P.; Archer, David F.; Boyd, Norman; Braunstein, Glenn D.; Burger, Henry G.; Colditz, Graham A.; Davis, Susan R.; Gambacciani, Marco; Gower, Barbara A.; Henderson, Victor W.; Jarjour, Wael N.; Karas, Richard H.; Kleerekoper, Michael; Lobo, Roger A.; Manson, Joann E.; Marsden, Jo; Martin, Kathryn A.; Martin, Lisa; Pinkerton, Joann V.; Rubinow, David R.; Teede, Helena; Thiboutot, Diane M.; Utian, Wulf H. (2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287288  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287288'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287288" class="external text external">"Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement"</a>. <i>The Journal of Clinical Endocrinology and Metabolism</i>. <b>95</b> (7_supplement_1): s1–s66. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2009-2509  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2009-2509'" tppabs="https://doi.org/10.1210%2Fjc.2009-2509" class="external text external">10.1210/jc.2009-2509</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287288  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287288'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287288" class="external text external">6287288</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20566620  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20566620'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20566620" class="external text external">20566620</a>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite id="CITEREFMueck_AOSeeger_HBühling_KJ.2009" class="citation journal cs1">Mueck AO; Seeger H; Bühling KJ. (2009). "Use of dydrogesterone in hormone replacement therapy". <i>Maturitas</i>. 65 Suppl 1: S51–60. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.09.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.09.013'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.09.013" class="external text external">10.1016/j.maturitas.2009.09.013</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19836909  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19836909'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19836909" class="external text external">19836909</a>.</cite></span></li><li id="cite_note-Muller1998-35"> <span id="mw-reference-text-cite_note-Muller1998-35" class="mw-reference-text"><cite id="CITEREFMuller1998" class="citation book cs1">Muller (19 June 1998). <a href="javascript:if(confirm('https://books.google.com/books?id=2HBPHmclMWIC&pg=PA407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2HBPHmclMWIC&pg=PA407'" tppabs="https://books.google.com/books?id=2HBPHmclMWIC&pg=PA407" class="external text external"><i>European Drug Index: European Drug Registrations, Fourth Edition</i></a>. CRC Press. pp.<span>&nbsp;</span>407–. ISBN<span>&nbsp;</span><bdi>978-3-7692-2114-5</bdi>.</cite></span></li><li id="cite_note-ChyeTeng2014-36"> <span id="mw-reference-text-cite_note-ChyeTeng2014-36" class="mw-reference-text"><cite id="CITEREFTan_Thiam_ChyeTan_Kim_TengTay_Eng_Hseon2014" class="citation book cs1">Tan Thiam Chye; Tan Kim Teng; Tay Eng Hseon (27 May 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=1j27CgAAQBAJ&pg=PA704  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=1j27CgAAQBAJ&pg=PA704'" tppabs="https://books.google.com/books?id=1j27CgAAQBAJ&pg=PA704" class="external text external"><i>Practical Obstetrics And Gynaecology Handbook For O&amp;g Clinicians And General Practitioners (2nd Edition)</i></a>. World Scientific. pp.<span>&nbsp;</span>704–. ISBN<span>&nbsp;</span><bdi>978-981-4522-96-0</bdi>.</cite></span></li><li id="cite_note-37"> <span id="mw-reference-text-cite_note-37" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.netdoctor.co.uk/womens-health/medicines/femoston.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.netdoctor.co.uk/womens-health/medicines/femoston.html'" tppabs="http://www.netdoctor.co.uk/womens-health/medicines/femoston.html" class="external text external">"Femoston"</a>. <i>NetDoctor.co.uk</i>.</cite></span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.nhlbi.nih.gov/whi/whi_faq.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nhlbi.nih.gov/whi/whi_faq.htm'" tppabs="https://www.nhlbi.nih.gov/whi/whi_faq.htm" class="external text external">"Questions and Answers About the WHI Postmenopausal Hormone Therapy Trials"</a>. <i>Women's Health Initiative</i>.</cite></span></li><li id="cite_note-Duphaston_10mg_Film-Coated_Tablets-39"> <span id="mw-reference-text-cite_note-Duphaston_10mg_Film-Coated_Tablets-39" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medicines.ie/medicine/5163/SPC/Duphaston+10mg+Film-Coated+Tablets/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicines.ie/medicine/5163/SPC/Duphaston+10mg+Film-Coated+Tablets/'" tppabs="http://www.medicines.ie/medicine/5163/SPC/Duphaston+10mg+Film-Coated+Tablets/" class="external text external">"Duphaston 10mg Film-Coated Tablets"</a>. <i>medicines.ie Ireland</i>.</cite></span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3321  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3321'" tppabs="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+3321" class="external text external">"DYDROGESTERONE"</a>. <i>United States National Library of Medicine</i>.</cite></span></li><li id="cite_note-DrugBank-41"> <span id="mw-reference-text-cite_note-DrugBank-41" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.drugbank.ca/drugs/DB00378  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.drugbank.ca/drugs/DB00378'" tppabs="http://www.drugbank.ca/drugs/DB00378" class="external text external">"Dydrogesterone"</a>. <i>DrugBank</i>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite id="CITEREFReerinkSchölerWesterhofQuerido1960" class="citation journal cs1">Reerink EH, Schöler HL, Westerhof P, Querido A, Kassenaar AA, Diczfalusy E, Tillinger KC (1960). "A new class of hormonally active steroids". <i>Nature</i>. <b>186</b> (4719): 168–186. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F186168a0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F186168a0'" tppabs="https://doi.org/10.1038%2F186168a0" class="external text external">10.1038/186168a0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14436886  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14436886'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14436886" class="external text external">14436886</a>.</cite></span></li><li id="cite_note-SchindlerCampagnoli2003-43"> <span id="mw-reference-text-cite_note-SchindlerCampagnoli2003-43" class="mw-reference-text"><cite id="CITEREFSchindlerCampagnoliDruckmannHuber2003" class="citation journal cs1">Schindler, Adolf E; Campagnoli, Carlo; Druckmann, René; Huber, Johannes; Pasqualini, Jorge R; Schweppe, Karl W; Thijssen, Jos H.H (2003). "Classification and pharmacology of progestins". <i>Maturitas</i>. <b>46</b>: 7–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2003.09.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2003.09.014'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2003.09.014" class="external text external">10.1016/j.maturitas.2003.09.014</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0378-5122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0378-5122'" tppabs="https://www.worldcat.org/issn/0378-5122" class="external text external">0378-5122</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14670641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14670641'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14670641" class="external text external">14670641</a>.</cite></span></li><li id="cite_note-pmid21376746-44"> <span id="mw-reference-text-cite_note-pmid21376746-44" class="mw-reference-text"><cite id="CITEREFRižnerBrožičDoucetteTurek-Etienne2011" class="citation journal cs1">Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Müller-Vieira U, Sonneveld E, van der Burg B, Böcker C, Husen B (May 2011). "Selectivity and potency of the retroprogesterone dydrogesterone in vitro". <i>Steroids</i>. <b>76</b> (6): 607–15. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.steroids.2011.02.043  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.steroids.2011.02.043'" tppabs="https://doi.org/10.1016%2Fj.steroids.2011.02.043" class="external text external">10.1016/j.steroids.2011.02.043</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21376746  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21376746'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21376746" class="external text external">21376746</a>.</cite></span></li><li id="cite_note-CabezaHeuze2014-45"> <span id="mw-reference-text-cite_note-CabezaHeuze2014-45" class="mw-reference-text"><cite id="CITEREFCabezaHeuzeSánchezGarrido2014" class="citation journal cs1">Cabeza, Marisa; Heuze, Yvonne; Sánchez, Araceli; Garrido, Mariana; Bratoeff, Eugene (2014). "Recent advances in structure of progestins and their binding to progesterone receptors". <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i>. <b>30</b> (1): 152–159. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F14756366.2014.895719  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F14756366.2014.895719'" tppabs="https://doi.org/10.3109%2F14756366.2014.895719" class="external text external">10.3109/14756366.2014.895719</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1475-6366  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1475-6366'" tppabs="https://www.worldcat.org/issn/1475-6366" class="external text external">1475-6366</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24666307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24666307'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24666307" class="external text external">24666307</a>.</cite></span></li><li id="cite_note-ColomboFerraboschi2006-46"> <span id="mw-reference-text-cite_note-ColomboFerraboschi2006-46" class="mw-reference-text"><cite id="CITEREFColomboFerraboschiPrestileoToma2006" class="citation journal cs1">Colombo, Diego; Ferraboschi, Patrizia; Prestileo, Paolo; Toma, Lucio (2006). "A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy". <i>The Journal of Steroid Biochemistry and Molecular Biology</i>. <b>98</b> (1): 56–62. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jsbmb.2005.07.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jsbmb.2005.07.009'" tppabs="https://doi.org/10.1016%2Fj.jsbmb.2005.07.009" class="external text external">10.1016/j.jsbmb.2005.07.009</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0960-0760  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0960-0760'" tppabs="https://www.worldcat.org/issn/0960-0760" class="external text external">0960-0760</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16216490  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16216490'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16216490" class="external text external">16216490</a>.</cite></span></li><li id="cite_note-Schindler2009-47"> <span id="mw-reference-text-cite_note-Schindler2009-47" class="mw-reference-text"><cite id="CITEREFSchindler2009" class="citation journal cs1">Schindler, Adolf E. (2009). "Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium". <i>Maturitas</i>. <b>65</b>: S3–S11. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.10.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.10.011'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.10.011" class="external text external">10.1016/j.maturitas.2009.10.011</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0378-5122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0378-5122'" tppabs="https://www.worldcat.org/issn/0378-5122" class="external text external">0378-5122</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19969432  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19969432'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19969432" class="external text external">19969432</a>.</cite></span></li><li id="cite_note-pmid29981319-48"> <span id="mw-reference-text-cite_note-pmid29981319-48" class="mw-reference-text"><cite id="CITEREFYasudaSumiMurataKida2018" class="citation journal cs1">Yasuda K, Sumi GI, Murata H, Kida N, Kido T, Okada H (August 2018). "The steroid hormone dydrogesterone inhibits myometrial contraction independently of the progesterone/progesterone receptor pathway". <i>Life Sci</i>. <b>207</b>: 508–515. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.lfs.2018.07.004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.lfs.2018.07.004'" tppabs="https://doi.org/10.1016%2Fj.lfs.2018.07.004" class="external text external">10.1016/j.lfs.2018.07.004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29981319  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29981319'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29981319" class="external text external">29981319</a>.</cite></span></li><li id="cite_note-BorisStevenson1966-49"> <span id="mw-reference-text-cite_note-BorisStevenson1966-49" class="mw-reference-text"><cite id="CITEREFBorisStevensonTrmal1966" class="citation journal cs1">Boris, Alfred; Stevenson, Richard H.; Trmal, Thelma (1966). "Some studies of the endocrine properties of dydrogesterone". <i>Steroids</i>. <b>7</b> (1): 1–10. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0039-128X%2866%2990131-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0039-128X%2866%2990131-0'" tppabs="https://doi.org/10.1016%2F0039-128X%2866%2990131-0" class="external text external">10.1016/0039-128X(66)90131-0</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0039-128X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0039-128X'" tppabs="https://www.worldcat.org/issn/0039-128X" class="external text external">0039-128X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/5920860  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/5920860'" tppabs="https://pubmed.ncbi.nlm.nih.gov/5920860" class="external text external">5920860</a>.</cite></span></li><li id="cite_note-Mittal2013-50"> <span id="mw-reference-text-cite_note-Mittal2013-50" class="mw-reference-text"><cite id="CITEREFSuneeta_Mittal2013" class="citation book cs1">Suneeta Mittal (12 July 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=IF-hYuUy7j0C&pg=PT42  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=IF-hYuUy7j0C&pg=PT42'" tppabs="https://books.google.com/books?id=IF-hYuUy7j0C&pg=PT42" class="external text external"><i>Threatened Miscarriage - ECAB</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>42–. ISBN<span>&nbsp;</span><bdi>978-81-312-3233-0</bdi>.</cite></span></li><li id="cite_note-pmid22078182-51"> <span id="mw-reference-text-cite_note-pmid22078182-51" class="mw-reference-text"><cite id="CITEREFEndrikatGerlingerRichardRosenbaum2011" class="citation journal cs1">Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". <i>Contraception</i>. <b>84</b> (6): 549–57. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.contraception.2011.04.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.contraception.2011.04.009'" tppabs="https://doi.org/10.1016%2Fj.contraception.2011.04.009" class="external text external">10.1016/j.contraception.2011.04.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22078182  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22078182'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22078182" class="external text external">22078182</a>.</cite></span></li><li id="cite_note-EskesHein1970-52"> <span id="mw-reference-text-cite_note-EskesHein1970-52" class="mw-reference-text"><cite id="CITEREFEskesHeinStolteKars-Villanueva1970" class="citation journal cs1">Eskes, T.K.A.B.; Hein, P.R.; Stolte, L.A.M.; Kars-Villanueva, E.B.; Crone, A.; Braaksma, J.T.; Janssens, J. (1970). "Influence of dydrogesterone on the activity of the nonpregnant human uterus". <i>American Journal of Obstetrics and Gynecology</i>. <b>106</b> (8): 1235–1241. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0002-9378%2870%2990524-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0002-9378%2870%2990524-7'" tppabs="https://doi.org/10.1016%2F0002-9378%2870%2990524-7" class="external text external">10.1016/0002-9378(70)90524-7</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0002-9378  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0002-9378'" tppabs="https://www.worldcat.org/issn/0002-9378" class="external text external">0002-9378</a>.</cite></span></li><li id="cite_note-HorskyPresl2012-53"> <span id="mw-reference-text-cite_note-HorskyPresl2012-53" class="mw-reference-text"><cite id="CITEREFJ._HorskyJ._Presl2012" class="citation book cs1">J. Horsky; J. Presl (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA329'" tppabs="https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA329" class="external text external"><i>Ovarian Function and its Disorders: Diagnosis and Therapy</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>329–330. ISBN<span>&nbsp;</span><bdi>978-94-009-8195-9</bdi>.</cite></span></li><li id="cite_note-pmid679688-54"> <span id="mw-reference-text-cite_note-pmid679688-54" class="mw-reference-text"><cite id="CITEREFTaubert1978" class="citation book cs1">Taubert HD (1978). <i>Luteal phase insufficiency</i>. <i>Contrib Gynecol Obstet</i>. Contributions to Gynecology and Obstetrics. <b>4</b>. pp.<span>&nbsp;</span>78–113. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000401245  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000401245'" tppabs="https://doi.org/10.1159%2F000401245" class="external text external">10.1159/000401245</a>. ISBN<span>&nbsp;</span><bdi>978-3-8055-2791-0</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/679688  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/679688'" tppabs="https://pubmed.ncbi.nlm.nih.gov/679688" class="external text external">679688</a>. <q>Fig. 17. Lack of hyperthermic effect of retroprogesterone derivative (Trengestone).</q></cite></span></li><li id="cite_note-Henzl1978-55"> <span id="mw-reference-text-cite_note-Henzl1978-55" class="mw-reference-text"><cite id="CITEREFM.R._Henzl1978" class="citation book cs1">M.R. Henzl (1978). "Natural and Synthetic Female Sex Hormones".  In S.S.C. Yen; R.B. Jaffe (eds.). <i>Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management</i>. W.B. Saunders Co. pp.<span>&nbsp;</span>421–468. ISBN<span>&nbsp;</span><bdi>978-0721696256</bdi>.</cite></span></li><li id="cite_note-Lauritzen1988-56"> <span id="mw-reference-text-cite_note-Lauritzen1988-56" class="mw-reference-text"><cite id="CITEREFLauritzen1988" class="citation book cs1">Lauritzen, Christian (1988). "Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien" <span>[</span>Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles<span>]</span>.  In Hermann P. G. Schneider; Christian Lauritzen; Eberhard Nieschlag (eds.). <a href="javascript:if(confirm('https://books.google.com/books?id=v4HvAQAACAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=v4HvAQAACAAJ'" tppabs="https://books.google.com/books?id=v4HvAQAACAAJ" class="external text external"><i>Grundlagen und Klinik der Menschlichen Fortpflanzung</i></a> <span>[</span><i>Foundations and Clinic of Human Reproduction</i><span>]</span> (in German). Walter de Gruyter. pp.<span>&nbsp;</span>229–306. ISBN<span>&nbsp;</span><bdi>978-3110109689</bdi>. OCLC<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/oclc/35483492  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/35483492'" tppabs="https://www.worldcat.org/oclc/35483492" class="external text external">35483492</a>.</cite></span></li><li id="cite_note-pmid27898258-57"> <span id="mw-reference-text-cite_note-pmid27898258-57" class="mw-reference-text"><cite id="CITEREFYangHuZhangXu2017" class="citation journal cs1">Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D (February 2017). "Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis". <i>Gynecol. Endocrinol</i>. <b>33</b> (2): 87–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F09513590.2016.1248932  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F09513590.2016.1248932'" tppabs="https://doi.org/10.1080%2F09513590.2016.1248932" class="external text external">10.1080/09513590.2016.1248932</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27898258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27898258'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27898258" class="external text external">27898258</a>.</cite></span></li><li id="cite_note-pmid23651281-58"> <span id="mw-reference-text-cite_note-pmid23651281-58" class="mw-reference-text"><cite id="CITEREFSturdee2013" class="citation journal cs1">Sturdee DW (2013). <a href="javascript:if(confirm('http://www.repository.heartofengland.nhs.uk/278/1/Are%20progestins%20really%20necessary%20as%20part%20of%20a%20combined%20HRT%20regime.docx.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.repository.heartofengland.nhs.uk/278/1/Are%20progestins%20really%20necessary%20as%20part%20of%20a%20combined%20HRT%20regime.docx.pdf'" tppabs="http://www.repository.heartofengland.nhs.uk/278/1/Are%20progestins%20really%20necessary%20as%20part%20of%20a%20combined%20HRT%20regime.docx.pdf" class="external text external">"Are progestins really necessary as part of a combined HRT regimen?"</a> <span class="cs1-format">(PDF)</span>. <i>Climacteric</i>. 16 Suppl 1: 79–84. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F13697137.2013.803311  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F13697137.2013.803311'" tppabs="https://doi.org/10.3109%2F13697137.2013.803311" class="external text external">10.3109/13697137.2013.803311</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23651281  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23651281'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23651281" class="external text external">23651281</a>.</cite></span></li><li id="cite_note-pmid29852797-59"> <span id="mw-reference-text-cite_note-pmid29852797-59" class="mw-reference-text"><cite id="CITEREFGompelPlu-Bureau2018" class="citation journal cs1">Gompel A, Plu-Bureau G (August 2018). "Progesterone, progestins and the breast in menopause treatment". <i>Climacteric</i>. <b>21</b> (4): 326–332. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F13697137.2018.1476483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F13697137.2018.1476483'" tppabs="https://doi.org/10.1080%2F13697137.2018.1476483" class="external text external">10.1080/13697137.2018.1476483</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29852797  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29852797'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29852797" class="external text external">29852797</a>.</cite></span></li><li id="cite_note-pmid23835005-60"> <span id="mw-reference-text-cite_note-pmid23835005-60" class="mw-reference-text"><cite id="CITEREFStevensonPanayPexman-Fieth2013" class="citation journal cs1">Stevenson JC, Panay N, Pexman-Fieth C (September 2013). "Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety". <i>Maturitas</i>. <b>76</b> (1): 10–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2013.05.018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2013.05.018'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2013.05.018" class="external text external">10.1016/j.maturitas.2013.05.018</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23835005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23835005'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23835005" class="external text external">23835005</a>. <q>Dydrogesterone did not increase the risk of VTE associated with oral estrogen (odds ratio (OR) 0.9, 95% CI 0.4–2.3). Other progestogens (OR 3.9, 95% CI 1.5–10.0) were found to further increase the risk of VTE associated with oral estrogen (OR 4.2, 95% CI 1.5–11.6).</q></cite></span></li><li id="cite_note-pmid19565370-61"> <span id="mw-reference-text-cite_note-pmid19565370-61" class="mw-reference-text"><cite id="CITEREFSchneiderJickMeier2009" class="citation journal cs1">Schneider C, Jick SS, Meier CR (October 2009). "Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations". <i>Climacteric</i>. <b>12</b> (5): 445–53. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F13697130902780853  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F13697130902780853'" tppabs="https://doi.org/10.1080%2F13697130902780853" class="external text external">10.1080/13697130902780853</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19565370  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19565370'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19565370" class="external text external">19565370</a>. <q>The adjusted relative risk of developing a VTE tended to be lower for E/D users (OR 0.84; 95% CI 0.37–1.92) than for users of other HRT (OR 1.42; 95% CI 1.10–1.82), compared to non-users.</q></cite></span></li><li id="cite_note-pmid26512775-62"> <span id="mw-reference-text-cite_note-pmid26512775-62" class="mw-reference-text"><cite id="CITEREFPrior2015" class="citation journal cs1">Prior JC (December 2015). "Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence". <i>Curr Opin Endocrinol Diabetes Obes</i>. <b>22</b> (6): 495–501. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FMED.0000000000000205  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FMED.0000000000000205'" tppabs="https://doi.org/10.1097%2FMED.0000000000000205" class="external text external">10.1097/MED.0000000000000205</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26512775  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26512775'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26512775" class="external text external">26512775</a>.</cite></span></li><li id="cite_note-SayeghAwwad2017-63"> <span id="mw-reference-text-cite_note-SayeghAwwad2017-63" class="mw-reference-text"><cite id="CITEREFSayeghAwwad2017" class="citation book cs1">Sayegh, Raja; Awwad, Johnny T. (2017). "Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive". <i>Essentials of Menopause Management</i>. pp.<span>&nbsp;</span>13–43. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-319-42451-4_2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-319-42451-4_2'" tppabs="https://doi.org/10.1007%2F978-3-319-42451-4_2" class="external text external">10.1007/978-3-319-42451-4_2</a>. ISBN<span>&nbsp;</span><bdi>978-3-319-42449-1</bdi>.</cite></span></li><li id="cite_note-pmid19935019-64"> <span id="mw-reference-text-cite_note-pmid19935019-64" class="mw-reference-text"><cite id="CITEREFJaakkolaLyytinenPukkalaYlikorkala2009" class="citation journal cs1">Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O (December 2009). "Endometrial cancer in postmenopausal women using estradiol-progestin therapy". <i>Obstet Gynecol</i>. <b>114</b> (6): 1197–204. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FAOG.0b013e3181bea950  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FAOG.0b013e3181bea950'" tppabs="https://doi.org/10.1097%2FAOG.0b013e3181bea950" class="external text external">10.1097/AOG.0b013e3181bea950</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19935019  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19935019'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19935019" class="external text external">19935019</a>.</cite></span></li><li id="cite_note-pmid23758160-65"> <span id="mw-reference-text-cite_note-pmid23758160-65" class="mw-reference-text"><cite id="CITEREFNeubauerMaZhouYu2013" class="citation journal cs1">Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, Fehm T, Mueck AO (October 2013). "Possible role of PGRMC1 in breast cancer development". <i>Climacteric</i>. <b>16</b> (5): 509–13. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F13697137.2013.800038  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F13697137.2013.800038'" tppabs="https://doi.org/10.3109%2F13697137.2013.800038" class="external text external">10.3109/13697137.2013.800038</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23758160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23758160'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23758160" class="external text external">23758160</a>.</cite></span></li><li id="cite_note-pmid31512725-66"> <span id="mw-reference-text-cite_note-pmid31512725-66" class="mw-reference-text"><cite id="CITEREFTrabertShermanKannanStanczyk2019" class="citation journal cs1">Trabert B, Sherman ME, Kannan N, Stanczyk FZ (September 2019). <a href="javascript:if(confirm('https://doi.org/10.1210/endrev/bnz001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210/endrev/bnz001'" tppabs="https://doi.org/10.1210/endrev/bnz001" class="external text external">"Progesterone and breast cancer"</a>. <i>Endocr. Rev</i>. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1210%2Fendrev%2Fbnz001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fendrev%2Fbnz001'" tppabs="https://doi.org/10.1210%2Fendrev%2Fbnz001" class="external text external">10.1210/endrev/bnz001</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31512725  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31512725'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31512725" class="external text external">31512725</a>.</cite></span></li><li id="cite_note-:2-67"> <span id="mw-reference-text-cite_note-:2-67" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.old.health.gov.il/units/pharmacy/trufot/alonim/duphaston_dr_1272874913497.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.old.health.gov.il/units/pharmacy/trufot/alonim/duphaston_dr_1272874913497.pdf'" tppabs="http://www.old.health.gov.il/units/pharmacy/trufot/alonim/duphaston_dr_1272874913497.pdf" class="external text external">"Duphaston Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. <i>Ministry of Health (Israel)</i>.</cite></span></li><li id="cite_note-Carp2015-68"> <span id="mw-reference-text-cite_note-Carp2015-68" class="mw-reference-text"><cite class="citation journal cs1">"Recurrent Pregnancy Loss. Causes, Controversies, and Treatment". <i>Second Edition</i>. 2015.</cite></span></li><li id="cite_note-Springer2013-69"> <span id="mw-reference-text-cite_note-Springer2013-69" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=t8GpBgAAQBAJ&pg=PA10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=t8GpBgAAQBAJ&pg=PA10'" tppabs="https://books.google.com/books?id=t8GpBgAAQBAJ&pg=PA10" class="external text external"><i>Die Gestagene</i></a>. Springer-Verlag. 27 November 2013. pp.<span>&nbsp;</span>10–, 275–276. ISBN<span>&nbsp;</span><bdi>978-3-642-99941-3</bdi>.</cite></span></li><li id="cite_note-70"> <span id="mw-reference-text-cite_note-70" class="mw-reference-text"><cite class="citation journal cs1">Schindler, AE (Dec 2009). "Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium". <i>Maturitas</i>. 65 Suppl 1: S3–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.10.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.10.011'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.10.011" class="external text external">10.1016/j.maturitas.2009.10.011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19969432  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19969432'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19969432" class="external text external">19969432</a>.</cite></span></li><li id="cite_note-71"> <span id="mw-reference-text-cite_note-71" class="mw-reference-text"><cite id="CITEREFQueisser-Luft_A2009" class="citation journal cs1">Queisser-Luft A (3 February 2009). "Dydrogesterone use during pregnancy: overview of birth defects reported since 1977". <i>Early Hum Dev</i>. <b>85</b> (6): 375–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.earlhumdev.2008.12.016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.earlhumdev.2008.12.016'" tppabs="https://doi.org/10.1016%2Fj.earlhumdev.2008.12.016" class="external text external">10.1016/j.earlhumdev.2008.12.016</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19193503  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19193503'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19193503" class="external text external">19193503</a>.</cite></span></li><li id="cite_note-Freedman1986-72"> <span id="mw-reference-text-cite_note-Freedman1986-72" class="mw-reference-text"><cite id="CITEREFWarren_Freedman1986" class="citation book cs1">Warren Freedman (1986). <a href="javascript:if(confirm('https://books.google.com/books?id=k85WAAAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=k85WAAAAIAAJ'" tppabs="https://books.google.com/books?id=k85WAAAAIAAJ" class="external text external"><i>International Products Liability</i></a>. Kluwer Law Book Publishers. ISBN<span>&nbsp;</span><bdi>978-0-930273-10-1</bdi>. <q>Duphaston was removed from the market in 1979 or about two years after the FDA required the defendant to place warnings on the product.</q></cite></span></li><li id="cite_note-FDA-73"> <span id="mw-reference-text-cite_note-FDA-73" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017388  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017388'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017388" class="external text external">"FDA Approved Drugs"</a>. <i>U.S. Food &amp; Drug Administration</i>.</cite></span></li><li id="cite_note-Drugs.com-74"> <span id="mw-reference-text-cite_note-Drugs.com-74" class="mw-reference-text"><a href="javascript:if(confirm('https://www.drugs.com/international/dydrogesterone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/dydrogesterone.html'" tppabs="https://www.drugs.com/international/dydrogesterone.html" class="external free external">https://www.drugs.com/international/dydrogesterone.html</a></span></li><li id="cite_note-GöretzlehnerLauritzen2012-75"> <span id="mw-reference-text-cite_note-GöretzlehnerLauritzen2012-75" class="mw-reference-text"><cite id="CITEREFGunther_GöretzlehnerChristian_LauritzenThomas_RömerWinfried_Rossmanith2012" class="citation book cs1">Gunther Göretzlehner; Christian Lauritzen; Thomas Römer; Winfried Rossmanith (1 January 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=TIs2WhfYzZ4C&pg=PA148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=TIs2WhfYzZ4C&pg=PA148'" tppabs="https://books.google.com/books?id=TIs2WhfYzZ4C&pg=PA148" class="external text external"><i>Praktische Hormontherapie in der Gynäkologie</i></a>. Walter de Gruyter. pp.<span>&nbsp;</span>148–. ISBN<span>&nbsp;</span><bdi>978-3-11-024568-4</bdi>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<div class="div-col columns column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em;   ">
<ul><li><cite id="CITEREFFosterBalfour1997" class="citation journal cs1">Foster RH, Balfour JA (October 1997). "Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women". <i>Drugs Aging</i>. <b>11</b> (4): 309–32. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00002512-199711040-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00002512-199711040-00006'" tppabs="https://doi.org/10.2165%2F00002512-199711040-00006" class="external text external">10.2165/00002512-199711040-00006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9342560  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9342560'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9342560" class="external text external">9342560</a>.</cite></li>
<li><cite id="CITEREFGruberHuber2005" class="citation journal cs1">Gruber CJ, Huber JC (December 2005). "The role of dydrogesterone in recurrent (habitual) abortion". <i>J. Steroid Biochem. Mol. Biol</i>. <b>97</b> (5): 426–30. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jsbmb.2005.08.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jsbmb.2005.08.009'" tppabs="https://doi.org/10.1016%2Fj.jsbmb.2005.08.009" class="external text external">10.1016/j.jsbmb.2005.08.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16188436  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16188436'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16188436" class="external text external">16188436</a>.</cite></li>
<li><cite id="CITEREFSeegerMueck2007" class="citation journal cs1">Seeger H, Mueck AO (October 2007). "Effects of dydrogesterone on the vascular system". <i>Gynecol. Endocrinol</i>. 23 Suppl 1: 2–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F09513590701584998  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F09513590701584998'" tppabs="https://doi.org/10.1080%2F09513590701584998" class="external text external">10.1080/09513590701584998</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17943533  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17943533'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17943533" class="external text external">17943533</a>.</cite></li>
<li><cite id="CITEREFSimonciniMannellaPluchinoGenazzani2007" class="citation journal cs1">Simoncini T, Mannella P, Pluchino N, Genazzani AR (October 2007). "Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels". <i>Gynecol. Endocrinol</i>. 23 Suppl 1: 9–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F09513590701585094  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F09513590701585094'" tppabs="https://doi.org/10.1080%2F09513590701585094" class="external text external">10.1080/09513590701585094</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17943534  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17943534'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17943534" class="external text external">17943534</a>.</cite></li>
<li><cite id="CITEREFQueisser-Luft2009" class="citation journal cs1">Queisser-Luft A (June 2009). "Dydrogesterone use during pregnancy: overview of birth defects reported since 1977". <i>Early Hum. Dev</i>. <b>85</b> (6): 375–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.earlhumdev.2008.12.016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.earlhumdev.2008.12.016'" tppabs="https://doi.org/10.1016%2Fj.earlhumdev.2008.12.016" class="external text external">10.1016/j.earlhumdev.2008.12.016</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19193503  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19193503'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19193503" class="external text external">19193503</a>.</cite></li>
<li><cite id="CITEREFMueckSeegerBühling2009" class="citation journal cs1">Mueck AO, Seeger H, Bühling KJ (December 2009). "Use of dydrogesterone in hormone replacement therapy". <i>Maturitas</i>. 65 Suppl 1: S51–60. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.09.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.09.013'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.09.013" class="external text external">10.1016/j.maturitas.2009.09.013</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19836909  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19836909'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19836909" class="external text external">19836909</a>.</cite></li>
<li><cite id="CITEREFSchindler2009" class="citation journal cs1">Schindler AE (December 2009). "Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium". <i>Maturitas</i>. 65 Suppl 1: S3–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2009.10.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2009.10.011'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2009.10.011" class="external text external">10.1016/j.maturitas.2009.10.011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19969432  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19969432'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19969432" class="external text external">19969432</a>.</cite></li>
<li><cite id="CITEREFSchindler2011" class="citation journal cs1">Schindler AE (February 2011). "Dydrogesterone and other progestins in benign breast disease: an overview". <i>Arch. Gynecol. Obstet</i>. <b>283</b> (2): 369–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00404-010-1456-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00404-010-1456-7'" tppabs="https://doi.org/10.1007%2Fs00404-010-1456-7" class="external text external">10.1007/s00404-010-1456-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20383772  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20383772'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20383772" class="external text external">20383772</a>.</cite></li>
<li><cite id="CITEREFCarp2012" class="citation journal cs1">Carp H (December 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297" class="external text external">"A systematic review of dydrogesterone for the treatment of threatened miscarriage"</a>. <i>Gynecol. Endocrinol</i>. <b>28</b> (12): 983–90. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F09513590.2012.702875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F09513590.2012.702875'" tppabs="https://doi.org/10.3109%2F09513590.2012.702875" class="external text external">10.3109/09513590.2012.702875</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518297" class="external text external">3518297</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22794306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22794306'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22794306" class="external text external">22794306</a>.</cite></li>
<li><cite id="CITEREFStevensonPanayPexman-Fieth2013" class="citation journal cs1">Stevenson JC, Panay N, Pexman-Fieth C (September 2013). "Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety". <i>Maturitas</i>. <b>76</b> (1): 10–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.maturitas.2013.05.018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.maturitas.2013.05.018'" tppabs="https://doi.org/10.1016%2Fj.maturitas.2013.05.018" class="external text external">10.1016/j.maturitas.2013.05.018</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23835005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23835005'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23835005" class="external text external">23835005</a>.</cite></li>
<li><cite id="CITEREFCarp2015" class="citation journal cs1">Carp H (June 2015). "A systematic review of dydrogesterone for the treatment of recurrent miscarriage". <i>Gynecol. Endocrinol</i>. <b>31</b> (6): 422–30. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F09513590.2015.1006618  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F09513590.2015.1006618'" tppabs="https://doi.org/10.3109%2F09513590.2015.1006618" class="external text external">10.3109/09513590.2015.1006618</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25765519  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25765519'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25765519" class="external text external">25765519</a>.</cite></li>
<li><cite id="CITEREFBarbosaSilvaNavarroFerriani2016" class="citation journal cs1">Barbosa MW, Silva LR, Navarro PA, Ferriani RA, Nastri CO, Martins WP (August 2016). <a href="javascript:if(confirm('https://doi.org/10.1002/uog.15814  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002/uog.15814'" tppabs="https://doi.org/10.1002/uog.15814" class="external text external">"Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials"</a>. <i>Ultrasound Obstet Gynecol</i>. <b>48</b> (2): 161–70. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1002%2Fuog.15814  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fuog.15814'" tppabs="https://doi.org/10.1002%2Fuog.15814" class="external text external">10.1002/uog.15814</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26577241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26577241'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26577241" class="external text external">26577241</a>.</cite></li>
<li><cite id="CITEREFMirzaPatkiPexman-Fieth2016" class="citation journal cs1">Mirza FG, Patki A, Pexman-Fieth C (2016). "Dydrogesterone use in early pregnancy". <i>Gynecol. Endocrinol</i>. <b>32</b> (2): 97–106. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F09513590.2015.1121982  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F09513590.2015.1121982'" tppabs="https://doi.org/10.3109%2F09513590.2015.1121982" class="external text external">10.3109/09513590.2015.1121982</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26800266  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26800266'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26800266" class="external text external">26800266</a>.</cite></li>
<li><cite id="CITEREFHudicSchindlerSzekeres-BarthoStray-Pedersen2016" class="citation journal cs1">Hudic I, Schindler AE, Szekeres-Bartho J, Stray-Pedersen B (September 2016). "Dydrogesterone and pre-term birth". <i>Horm Mol Biol Clin Investig</i>. <b>27</b> (3): 81–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2Fhmbci-2015-0064  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2Fhmbci-2015-0064'" tppabs="https://doi.org/10.1515%2Fhmbci-2015-0064" class="external text external">10.1515/hmbci-2015-0064</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26812800  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26812800'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26812800" class="external text external">26812800</a>.</cite></li>
<li><cite id="CITEREFRaghupathySzekeres-Bartho2016" class="citation journal cs1">Raghupathy R, Szekeres-Bartho J (August 2016). "Dydrogesterone and the immunology of pregnancy". <i>Horm Mol Biol Clin Investig</i>. <b>27</b> (2): 63–71. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2Fhmbci-2015-0062  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2Fhmbci-2015-0062'" tppabs="https://doi.org/10.1515%2Fhmbci-2015-0062" class="external text external">10.1515/hmbci-2015-0062</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26812877  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26812877'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26812877" class="external text external">26812877</a>.</cite></li>
<li><cite id="CITEREFMohamad_RaziSchindler2016" class="citation journal cs1">Mohamad Razi ZR, Schindler AE (August 2016). "Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension". <i>Horm Mol Biol Clin Investig</i>. <b>27</b> (2): 73–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2Fhmbci-2015-0070  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2Fhmbci-2015-0070'" tppabs="https://doi.org/10.1515%2Fhmbci-2015-0070" class="external text external">10.1515/hmbci-2015-0070</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27101553  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27101553'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27101553" class="external text external">27101553</a>.</cite></li>
<li><cite id="CITEREFSchindler2016" class="citation journal cs1">Schindler AE (August 2016). "Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook". <i>Horm Mol Biol Clin Investig</i>. <b>27</b> (2): 49–53. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2Fhmbci-2016-0028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2Fhmbci-2016-0028'" tppabs="https://doi.org/10.1515%2Fhmbci-2016-0028" class="external text external">10.1515/hmbci-2016-0028</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27662647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27662647'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27662647" class="external text external">27662647</a>.</cite></li>
<li><cite id="CITEREFLeeParkKimNorwitz2017" class="citation journal cs1">Lee HJ, Park TC, Kim JH, Norwitz E, Lee B (2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748117  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748117'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748117" class="external text external">"The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis"</a>. <i>Biomed Res Int</i>. <b>2017</b>: 3616875. doi:<a href="javascript:if(confirm('https://doi.org/10.1155%2F2017%2F3616875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1155%2F2017%2F3616875'" tppabs="https://doi.org/10.1155%2F2017%2F3616875" class="external text external">10.1155/2017/3616875</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748117  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748117'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748117" class="external text external">5748117</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29392134  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29392134'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29392134" class="external text external">29392134</a>.</cite></li>
<li><cite id="CITEREFGriesingerBlockeelTournaye2018" class="citation journal cs1">Griesinger G, Blockeel C, Tournaye H (May 2018). <a href="javascript:if(confirm('https://doi.org/10.1016/j.fertnstert.2018.03.034  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.fertnstert.2018.03.034'" tppabs="https://doi.org/10.1016/j.fertnstert.2018.03.034" class="external text external">"Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard?"</a>. <i>Fertil. Steril</i>. <b>109</b> (5): 756–762. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.fertnstert.2018.03.034  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.fertnstert.2018.03.034'" tppabs="https://doi.org/10.1016%2Fj.fertnstert.2018.03.034" class="external text external">10.1016/j.fertnstert.2018.03.034</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29778368  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29778368'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29778368" class="external text external">29778368</a>.</cite></li>
<li><cite id="CITEREFGriesingerTournayeMacklonPetraglia2019" class="citation journal cs1">Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, van Amsterdam P, Pexman-Fieth C, Fauser BC (February 2019). <a href="javascript:if(confirm('https://doi.org/10.1016/j.rbmo.2018.11.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.rbmo.2018.11.017'" tppabs="https://doi.org/10.1016/j.rbmo.2018.11.017" class="external text external">"Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction"</a>. <i>Reprod. Biomed. Online</i>. <b>38</b> (2): 249–259. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.rbmo.2018.11.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.rbmo.2018.11.017'" tppabs="https://doi.org/10.1016%2Fj.rbmo.2018.11.017" class="external text external">10.1016/j.rbmo.2018.11.017</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30595525  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30595525'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30595525" class="external text external">30595525</a>.</cite></li></ul>
</div>

<div role="navigation" class="navbox" aria-labelledby="Progestogens_and_antiprogestogens" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Progestogens_and_antiprogestogens" style="font-size:114%;margin:0 4em">Progestogens and antiprogestogens</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Progestogens<br>(and progestins)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="PR_agonists" scope="row" class="navbox-group" style="width:8em;;text-align:center;"><abbr>PR</abbr> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Progesterone derivatives:</i> Progesterone</li>
<li>Quingestrone</li></ul>

<ul><li><i>Retroprogesterone derivatives:</i> <a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li>Trengestone</li></ul>

<ul><li><i>17α-Hydroxyprogesterone (and closely related) derivatives:</i> <i>17α-Hydroxylated:</i> Acetomepregenol (mepregenol diacetate)</li>
<li>Algestone acetophenide (dihydroxyprogesterone acetophenide)</li>
<li>Anagestone acetate</li>
<li>Chlormadinone acetate</li>
<li>Chlormethenmadinone acetate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone acetate</li>
<li>Flugestone acetate (flurogestone acetate)</li>
<li>Flumedroxone acetate</li>
<li>Hydroxyprogesterone acetate</li>
<li>Hydroxyprogesterone caproate</li>
<li>Hydroxyprogesterone heptanoate</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a><sup>#</sup></li>
<li>Megestrol acetate</li>
<li>Melengestrol acetate</li>
<li>Methenmadinone acetate</li>
<li>Osaterone acetate</li>
<li>Pentagestrone acetate</li>
<li>Proligestone; <i>17α-Methylated:</i> Medrogestone; <i>Others:</i> Haloprogesterone</li></ul>

<ul><li><i>19-Norprogesterone derivatives:</i> <i>17α-Hydroxylated:</i> Gestonorone caproate (gestronol hexanoate)</li>
<li>Nomegestrol acetate</li>
<li>Norgestomet</li>
<li>Segesterone acetate (nestorone, elcometrine); <i>17α-Methylated:</i> Demegestone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Trimegestone</li></ul>

<ul><li><i>Testosterone derivatives:</i> <i>Estranes:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Dimethisterone</li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone</a></li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> <i>Estranes:</i> <a href="Allylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Allylestrenol" title="Allylestrenol">Allylestrenol</a></li>
<li>Altrenogest</li>
<li>Dienogest</li>
<li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li>
<li>Lynestrenol</li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone (norethindrone)</a><sup>#</sup></li>
<li>Norethisterone acetate</li>
<li>Norethisterone enanthate</li>
<li>Noretynodrel</li>
<li>Norgesterone</li>
<li>Norgestrienone</li>
<li>Normethandrone (methylestrenolone)</li>
<li>Norvinisterone</li>
<li>Oxendolone</li>
<li>Quingestanol acetate</li>
<li>Tibolone; <i>Gonanes:</i> <a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a><sup>#</sup></li>
<li>Norelgestromin</li>
<li><a href="Norgestimate.htm" tppabs="https://ptable.com/wiki/compounds/A/Norgestimate" title="Norgestimate">Norgestimate</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li></ul>

<ul><li><i>Spirolactone derivatives:</i> <a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li></ul>

<ul><li><i>Others:</i> Anabolic–androgenic steroids (e.g., <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">nandrolone</a> and esters, trenbolone and esters, <a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">ethylestrenol</a>, norethandrolone, others)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antiprogestogens</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:8em;;text-align:center;"><abbr>SPRMs</abbr></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Telapristone<sup>§</sup></li>
<li>Ulipristal acetate</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:8em;;text-align:center;"><abbr>PR</abbr> antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aglepristone</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div>
<dl><dt>See also</dt>
<dd>Progesterone receptor modulators</dd>
<dd>Androgens and antiandrogens</dd>
<dd>Estrogens and antiestrogens</dd>
<dd>List of progestogens</dd></dl></div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Progesterone_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Progesterone_receptor_modulators" style="font-size:114%;margin:0 4em">Progesterone receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Progesterone derivatives:</i> 3β-Dihydroprogesterone</li>
<li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>6α-Methylprogesterone</li>
<li>9α-Bromo-11-ketoprogesterone</li>
<li>11-Dehydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycorticosterone</a></li>
<li>16α-Hydroxyprogesterone</li>
<li><span class="new">17α-Methyl-11-deoxycorticosterone acetate</span></li>
<li>20α-Dihydroprogesterone</li>
<li>20β-Dihydroprogesterone</li>
<li>Dimepregnen</li>
<li><a href="Diosgenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Diosgenin" title="Diosgenin">Diosgenin</a></li>
<li>P1-185</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Progesterone 3-acetyl enol ether</li>
<li>Quingestrone</li></ul>

<ul><li><i>Retroprogesterone derivatives:</i> 20α-Dihydrodydrogesterone</li>
<li>20α-Dihydrotrengestone</li>
<li>DU-41164</li>
<li>DU-41165</li>
<li><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li>Retroprogesterone</li>
<li>Ro 6-3129</li>
<li>Trengestone</li></ul>

<ul><li><i>17α-Substituted progesterone derivatives:</i> 6α-Methyl-17α-bromoprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>16-Methylene-17α-hydroxyprogesterone acetate</li>
<li>17α-Bromoprogesterone</li>
<li>17α-Hydroxyprogesterone (hydroxyprogesterone)</li>
<li>17α-Methylprogesterone</li>
<li>Acetomepregenol (mepregenol diacetate)</li>
<li>Algestone</li>
<li>Algestone acetonide</li>
<li>Algestone acetophenide</li>
<li>Anagestone</li>
<li>Anagestone acetate</li>
<li><span class="new">Bromethenmadinone</span></li>
<li>Bromethenmadinone acetate</li>
<li>Butagest (buterol)</li>
<li>Chlormadinone</li>
<li>Chlormadinone acetate</li>
<li>Chlormadinone caproate</li>
<li><span class="new">Chlormethenmadinone</span></li>
<li>Chlormethenmadinone acetate</li>
<li>Cismadinone</li>
<li>Cismadinone acetate</li>
<li>Clogestone</li>
<li>Clogestone acetate</li>
<li>Clomegestone</li>
<li>Clomegestone acetate</li>
<li>Cymegesolate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone</li>
<li>Delmadinone acetate</li>
<li>Edogestrone</li>
<li>Flugestone</li>
<li>Flugestone acetate</li>
<li><a href="Fluorometholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorometholone" title="Fluorometholone">Fluorometholone</a></li>
<li>Fluorometholone acetate</li>
<li>Flumedroxone</li>
<li>Flumedroxone acetate</li>
<li>Fluoromedroxyprogesterone acetate</li>
<li>Gestaclone</li>
<li>Haloprogesterone</li>
<li>Hydromadinone</li>
<li>Hydromadinone acetate</li>
<li>Hydroxyprogesterone acetate</li>
<li>Hydroxyprogesterone caproate (hydroxyprogesterone hexanoate)</li>
<li>Hydroxyprogesterone heptanoate (hydroxyprogesterone enanthate)</li>
<li>Hydroxyprogesterone heptanoate benzilic acid hydrazone</li>
<li>Mecigestone (pentarane B)</li>
<li>Medrogestone</li>
<li><a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">Medroxyprogesterone</a></li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Medroxyprogesterone caproate</li>
<li><a href="Megestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Megestrol" title="Megestrol">Megestrol</a></li>
<li>Megestrol acetate</li>
<li>Megestrol caproate</li>
<li>Melengestrol</li>
<li>Melengestrol acetate</li>
<li>Methenmadinone</li>
<li>Methenmadinone acetate</li>
<li>Methenmadinone caproate</li>
<li>Mometasone</li>
<li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone furoate</a></li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Pentagestrone</li>
<li>Pentagestrone acetate</li>
<li>Pentarane A</li>
<li>Proligestone</li></ul>

<ul><li><i>19-Norprogesterone derivatives:</i> 17α-Methyl-19-norprogesterone</li>
<li>18-Methylsegesterone acetate</li>
<li>19-Norprogesterone</li>
<li>Amadinone</li>
<li>Amadinone acetate</li>
<li>Demegestone</li>
<li><span class="new">Fluoro ethyl norprogesterone</span></li>
<li><span class="new">Fluoro furanyl norprogesterone</span></li>
<li>Gestadienol</li>
<li>Gestadienol acetate</li>
<li>Gestonorone acetate (gestronol acetate)</li>
<li>Gestonorone caproate (gestronol hexanoate)</li>
<li>Gestronol (gestonorone)</li>
<li>Nomegestrol</li>
<li>Nomegestrol acetate</li>
<li>Norgestomet</li>
<li>ORG-2058</li>
<li>Oxogestone</li>
<li>Oxogestone phenpropionate (xinogestone)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Segesterone</li>
<li>Segesterone acetate (nestorone)</li>
<li>Trimegestone</li></ul>

<ul><li><i>Testosterone derivatives:</i> Progestins: 6,6-Difluoronorethisterone</li>
<li>6,6-Difluoronorethisterone acetate</li>
<li>17α-Allyl-19-nortestosterone</li>
<li><a href="Allylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Allylestrenol" title="Allylestrenol">Allylestrenol</a></li>
<li>Altrenogest</li>
<li>Chloroethynylnorgestrel</li>
<li>Cingestol</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li>Dienogest</li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone</a></li>
<li>Ethynerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol</li>
<li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol</li>
<li>Lynestrenol phenylpropionate</li>
<li>Metynodiol</li>
<li>Metynodiol diacetate</li>
<li>Norelgestromin</li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone (norethindrone)</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li>Noretynodrel</li>
<li>Norgesterone</li>
<li><a href="Norgestimate.htm" tppabs="https://ptable.com/wiki/compounds/A/Norgestimate" title="Norgestimate">Norgestimate</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Norvinisterone</li>
<li>Oxendolone</li>
<li>Quingestanol</li>
<li>Quingestanol acetate</li>
<li>Tibolone</li>
<li>Tigestol</li>
<li>Tosagestin; Anabolic–androgenic steroids: 11β-Methyl-19-nortestosterone</li>
<li>11β-Methyl-19-nortestosterone dodecylcarbonate</li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol</li>
<li>Bolandiol dipropionate</li>
<li>Bolandione</li>
<li>Dimethisterone</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone</li>
<li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol (ethylnandrol)</a></li>
<li>Methyldienolone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone (R-1881)</a></li>
<li>Methoxydienone (methoxygonadiene)</li>
<li>Mibolerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a></li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethandrolone, normethisterone)</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li>
<li>Trenbolone (trienolone)</li>
<li>Trenbolone esters (e.g., trenbolone acetate, trenbolone enanthate)</li>
<li>Trendione</li>
<li>Trestolone</li>
<li>Trestolone acetate</li></ul>

<ul><li><i>Spirolactone derivatives:</i> Canrenoic acid</li>
<li>Canrenone</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Mespirenone</li>
<li>Potassium canrenoate</li>
<li>Prorenone</li>
<li>SC-5233 (spirolactone)</li>
<li>SC-8109</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li></ul>

<ul><li><i>Nonsteroidal:</i> 3,8-Dihydrodiligustilide</li>
<li>LG-2527</li>
<li><span class="new">LG-100128</span></li>
<li>Riligustilide</li>
<li><span class="new">RWJ-26819</span></li>
<li><span class="new">RWJ-49853</span></li>
<li><span class="new">RWJ-60130</span></li>
<li>Tanaproget</li>
<li>ZM-182345</li></ul>

<ul><li><i>Unknown:</i> ORG-47241</li>
<li>ORG-201745</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SPRMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Dihydroethisterone</li>
<li>5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li>
<li>Asoprisnil</li>
<li>Asoprisnil ecamate</li>
<li>Guggulsterone</li>
<li><span class="new">J1042</span></li>
<li><span class="new">LG-120838</span></li>
<li>Metapristone (RU-42633)</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone (RU-486)</a></li>
<li><span class="new">ORF-9371</span></li>
<li>ORF-9326</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RMI-12936</span></li>
<li>Telapristone</li>
<li>Ulipristal acetate</li>
<li>Vilaprisan</li>
<li><span class="new">ZK-137316</span></li></ul>

<ul><li><i>Nonsteroidal:</i> <a href="Apigenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Apigenin" title="Apigenin">Apigenin</a></li>
<li><a href="Kaempferol.htm" tppabs="https://ptable.com/wiki/compounds/A/Kaempferol" title="Kaempferol">Kaempferol</a></li>
<li><span class="new">LG-120920</span></li>
<li><a href="Naringenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Naringenin" title="Naringenin">Naringenin</a></li>
<li><span class="new">PRA-910</span></li>
<li><a href="Syringic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Syringic_acid" title="Syringic acid">Syringic acid</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Aglepristone</li>
<li>Lilopristone</li>
<li>Lonaprisan</li>
<li>Onapristone</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-31806</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RTI 3021–022</span></li>
<li>Toripristone</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> Darolutamide</li>
<li><span class="new">LG-001447</span></li>
<li><span class="new">LG-100127</span></li>
<li><span class="new">LG-100128</span></li>
<li><span class="new">LG-120830</span></li>
<li><span class="new">LG-121046</span></li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li><span class="new">ZM-150271</span></li>
<li><span class="new">ZM-172406</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>mPR</abbr><br>(<abbr>PAQR</abbr>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>5β-Dihydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycortisone (21-hydroxyprogesterone)</a></li>
<li>11-Deoxycortisol (17α,21-dihydroxyprogesterone)</li>
<li>17α-Hydroxyprogesterone</li>
<li><a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">Allopregnanolone</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>Androgen receptor modulators</dd>
<dd>Estrogen receptor modulators</dd>
<dd>List of progestogens</dd></dl>
</div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Mineralocorticoid_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Mineralocorticoid_receptor_modulators" style="font-size:114%;margin:0 4em">Mineralocorticoid receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>MR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>11-Dehydrocorticosterone (11-oxocorticosterone, 17-deoxycortisone)
<ul><li><span class="new">11-Dehydrocorticosterone acetate</span></li></ul></li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycorticosterone (desoxycortone, deoxycortone, desoxycorticosterone)</a>
<ul><li>Desoxycortone esters</li></ul></li>
<li>11-Deoxycortisol (cortodoxone, cortexolone)
<ul><li>Cortifen (cortiphen, kortifen)</li>
<li><span class="new">Cortodoxone acetate</span></li></ul></li>
<li>11β-Hydroxyprogesterone</li>
<li><span class="new">16α,18-Dihydroxy-11-deoxycorticosterone</span></li>
<li><span class="new">17α-Hydroxyaldosterone</span></li>
<li><span class="new">18-Hydroxy-11-deoxycorticosterone</span></li>
<li>19-Norprogesterone</li>
<li><a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">Aldosterone</a></li>
<li><a href="Corticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Corticosterone" title="Corticosterone">Corticosterone</a>
<ul><li><span class="new">Corticosterone acetate</span></li>
<li><span class="new">Corticosterone benzoate</span></li></ul></li>
<li><a href="Cortisol.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisol" title="Cortisol">Cortisol</a> (hydrocortisone)
<ul><li>Benzodrocortisone (hydrocortisone benzoate)</li>
<li><a href="Hydrocortamate.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydrocortamate" title="Hydrocortamate">Hydrocortamate (hydrocortisone diethylaminoacetate)</a></li>
<li>Hydrocortisone esters</li></ul></li>
<li><a href="Cortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cortisone" title="Cortisone">Cortisone</a>
<ul><li>Cortisone acetate</li></ul></li>
<li><a href="Fludrocortisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fludrocortisone" title="Fludrocortisone">Fludrocortisone (fludrocortone)</a>
<ul><li>Fludrocortisone acetate</li></ul></li>
<li>Mometasone
<ul><li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone furoate</a></li></ul></li>
<li><a href="Prednisolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisolone" title="Prednisolone">Prednisolone</a>
<ul><li>Prednazate</li>
<li>Prednazoline</li>
<li><a href="Prednicarbate.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednicarbate" title="Prednicarbate">Prednicarbate (prednisolone ethylcarbonate propionate)</a></li>
<li><a href="Prednimustine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednimustine" title="Prednimustine">Prednimustine</a></li>
<li>Prednisolamate (prednisolone diethylaminoacetate)</li>
<li>Prednisolone esters</li></ul></li>
<li><a href="Prednisone.htm" tppabs="https://ptable.com/wiki/compounds/A/Prednisone" title="Prednisone">Prednisone</a>
<ul><li>Prednisone esters</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 6β-Hydroxy-7α-thiomethylspironolactone</li>
<li><span class="new">7α-Acetylthio-17α-hydroxyprogesterone</span></li>
<li>7α-Thiomethylspironolactone (SC-26519)</li>
<li>7α-Thioprogesterone (SC-8365)</li>
<li>7α-Thiospironolactone (SC-24813)</li>
<li>16α-Hydroxyprogesterone</li>
<li>17α-Hydroxyprogesterone (hydroxyprogesterone)</li>
<li>18-Deoxyaldosterone</li>
<li><span class="new">18,19-Dinorprogesterone</span></li>
<li>Canrenoate potassium (potassium canrenoate)</li>
<li>Canrenoic acid (canrenoate)</li>
<li>Canrenone (canrenoate y-lactone)</li>
<li>Dicirenone</li>
<li>Dimethisterone</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li><a href="Eplerenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Eplerenone" title="Eplerenone">Eplerenone</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li>Guggulsterone</li>
<li>Hydroxyprogesterone caproate</li>
<li>Medrogestone</li>
<li>Mespirenone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Mexrenoate potassium</li>
<li>Mexrenoic acid (mexrenoate)</li>
<li>Mexrenone</li>
<li>Oxprenoic acid (oxprenoate)</li>
<li>Oxprenoate potassium (RU-28318)</li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Prorenoate potassium</li>
<li>Prorenoic acid (prorenoate)</li>
<li>Prorenone</li>
<li><span class="new">RO-14-9012</span></li>
<li><span class="new">RU-26752</span></li>
<li>SC-5233 (spirolactone)</li>
<li>SC-8109</li>
<li><span class="new">SC-11927 (CS-1)</span></li>
<li><span class="new">SC-19886</span></li>
<li><span class="new">SC-27169</span></li>
<li>Spirorenone</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spiroxasone</li>
<li>Tibolone</li>
<li>Trimegestone</li>
<li><span class="new">ZK-91587</span></li>
<li><span class="new">ZK-97894</span></li></ul>

<ul><li><i>Nonsteroidal:</i> <a href="Amlodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amlodipine" title="Amlodipine">Amlodipine</a></li>
<li>Apararenone</li>
<li>Benidipine</li>
<li><span class="new">BR-4628</span></li>
<li>Esaxerenone</li>
<li><a href="Felodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Felodipine" title="Felodipine">Felodipine</a></li>
<li>Finerenone</li>
<li><span class="new">Miricorilant (CORT-118335)</span></li>
<li><a href="Nifedipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nifedipine" title="Nifedipine">Nifedipine</a></li>
<li><a href="Nimodipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nimodipine" title="Nimodipine">Nimodipine</a></li>
<li><a href="Nitrendipine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nitrendipine" title="Nitrendipine">Nitrendipine</a></li>
<li><span class="new">PF-03882845</span></li>
<li><span class="new">SM-368229</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Mineralocorticoids and antimineralocorticoids</dd>
<dd>Glucocorticoid receptor modulators</dd>
<dd>List of corticosteroids</dd></dl>
</div></td></tr></tbody></table></div><span>
</span>









<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>